Article: Deletion of *Abi3/Gngt2* influences age-progressive amyloid β and tau pathologies in distinctive ways

Kristen R Ibanez¹, Karen N McFarland^{1,2}, Jennifer Phillips¹, Mariet Allen³, Christian Lessard¹,

Lillian Zobel¹, Elsa Gonzalez De La Cruz¹, Shivani Shah¹, Quan Vo¹, Xue Wang³, Zach

Quicksall³, Daniel Ryu¹, Cory Funk⁴, Nilufer Ertekin-Taner³, Stefan Prokop^{1,5,6}, Todd E

Golde^{1,6,7}, Paramita Chakrabarty^{1,6,7,} *

¹Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA.

²Department of Neurology, University of Florida, Gainesville, FL 32610, USA.

³Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.

⁴Institute for Systems Biology, Seattle, WA 98109, USA

⁵Department of Pathology, University of Florida, Gainesville, FL 32610, USA.

⁶McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.

⁷Department of Neuroscience, University of Florida, Gainesville, FL 32610, USA.

*Address correspondence to Paramita Chakrabarty 1275 Center Drive, BMS J484, Gainesville – 32610, USA. Email: <u>pchakrabarty@ufl.edu</u> Phone: 1-352-273-7271 Fax: 1-352-294-5060 ORC ID: 0000-0002-6226-3776

Keywords: Alzheimer's disease, plaque burden, neurofibrillary tangle, disease signature, risk factor, gene dose **Total word count** including references and expanded view information: 16,929 **Running Title**: Effect of Abi3 locus deletion on Aβ and tau

Abstract

The S209F variant of Abelson Interactor Protein 3 (ABI3) increases risk for Alzheimer's disease (AD), but little is known about ABI3 function. RNAscope showed Abi3 is expressed in microglial and non-microglial cells, though its increased expression appears to be driven in plaque-associated microglia. Here, we evaluated Abi3^{-/-} mice and document that both Abi3 and its overlapping gene, Gngt2, are disrupted in these mice. Expression of Abi3 and Gngt2 are tightly correlated, and elevated, in rodent models of AD. RNA-seq of the Abi3-Gngt2^{-/-} mice revealed robust induction of an AD-associated neurodegenerative signature, including upregulation of Trem2, Plcg2 and Tyrobp. In APP mice, loss of Abi3-Gngt2 resulted in a gene dose- and age-dependent reduction in A β deposition. Additionally, in *Abi3-Gngt2^{-/-}* mice, expression of a pro-aggregant form of human tau exacerbated tauopathy and astrocytosis. Further, the AD-associated S209F mutation alters the extent of ABI3 phosphorylation. These data provide an important experimental framework for understanding the role of Abi3-Gngt2 function in AD. Our studies also demonstrate that manipulation of glial function could have opposing effects on amyloid and tau pathology, highlighting the unpredictability of targeting such pathways in AD.

Introduction

Alzheimer's disease (AD) is associated with several canonical pathological hallmarks such as extracellular amyloid β (A β) deposits, intracellular neurofibrillary tangles (NFT) of tau protein and robust immune activation (Jack et al., 2018). Activation of innate immunity is an integral part of the AD pathological cascade, though its role is not fully understood due to the diversity and complexity of the immune signaling processes (Dansokho & Heneka, 2018, Golde, 2019, Hansen et al., 2018, Karran & De Strooper, 2016).

Recent genetic and transcriptomic data have highlighted the involvement of immune signaling processes in AD pathogenesis (Golde, 2019, Hansen et al., 2018, Karran & De Strooper, 2016, Shi & Holtzman, 2018). Several genes, whose expression is thought to be enriched in microglial cells, have been implicated as AD risk factors (Efthymiou & Goate, 2017, Walker, 2020). One of these recently identified genes encodes the Abl Interactor family member 3 (ABI3), also known as NESH (new molecule including SH3) (Conway et al., 2018, Sims et al., 2017). The S209F *AB13* variant (rs616338:p.Ser209Phe) increased the risk of AD (OR=1.43, p=4.5x10⁻¹⁰, MAF=0.008) (Conway et al., 2018, Sims et al., 2017) and has been validated in a secondary study (Wightman et al., 2021).

The ABI3 protein contains a Src homology 3 (SH3) domain, a homeobox homology domain and several proline-rich and serine-rich motifs (Miyazaki et al., 2000). Its putative function, largely based on analogy to function of other family members, is to regulate actin polymerization resulting in reduced ectopic metastasis of tumor cells and cell migration (Ichigotani et al., 2002). In the periphery, it is highly expressed in spleen, lymph node and appendix. In the brain, its

expression has been reported to be enriched in microglia with ramified or amoeboid morphology (Satoh et al., 2017). Single cell data from mouse brain suggests low level expression in microglia ((Yao et al., 2021); data available from: celltypes.brain-map.org). In the brain, it may also play a role in dendritic spine morphogenesis (Bae et al., 2012a). Though the function of ABI3 in Alzheimer's pathogenesis or any neurodegenerative disease is unknown, co-expression network analysis suggests a close functional relationship with at least two other notable AD related microglial genes, *TREM2* and *SPI1* (Sims et al., 2017).

Here we have evaluated expression of Abi3 in mouse models of AD pathologies and in bulk RNAseq studies of human brain. We find that Abi3 RNA is not just present in microglia but also in non-microglial cells. However, Abi3 mRNA increases seen in human AD and these mouse models appear to be driven by increases in microglia especially those surrounding amyloid plaques. We have also characterized an Abi3^{-/-} mouse line (B6N(Cg)-Abi3tm1.1(KOMP)Vlcg/J), and the effects of loss of Abi3 locus on amyloid and tau pathologies. Initial characterization using bulk RNAseq of the brain reveals loss of expression of an overlapping gene, Gngt2, indicating these mice are better referred to as Abi3-Gngt2^{-/-}. Notably, these mice showed early upregulation of an immune gene expression profile, characterized by increased levels of Trem2, Plcg2 and Tyrobp, that has been previously documented to be induced in rodent models of AD pathologies and AD brains. Haploinsufficiency (+/-) or complete knockout (-/-) of the Abi3-Gngt2 locus reduced A^β levels in an APP mouse model. This beneficial effect was diminished as the mice aged. In Abi3-Gngt2^{-/-} mice, overexpression of a pro-aggregant tau using neonatal delivery of adeno-associated viruses (AAV) resulted in increased tau pathology and astrocytosis. We further find that the S209F ABI3 variant alters phosphorylation of ABI3, providing initial insight into how this mutant may alter ABI3 function. These data further highlight the complexity of immunoproteostasis with respect to AD relevant pathologies (Golde, 2019), and reinforce the notion that factors that alter immune signaling often have opposing effects on amyloid and tau.

Results

ABI3 is expressed in microglia and neurons in mice and humans

Recent reports have confirmed *ABI3* as an AD risk gene (Conway et al., 2018, Sims et al., 2017, Wightman et al., 2021). *ABI3* has been reported to be a microglia-specific gene using single cell RNAseq (Yao et al., 2021, Zhang et al., 2014). Bulk RNAseq data reveals increased levels of ABI3 RNA relative to control cohorts in both the temporal cortex and cerebellum of human patients and in mouse models of amyloid and tau pathologies (Sims et al., 2017). In AD brains, ABI3 expression is significantly upregulated (p= 4.47E-03) (Sims et al., 2017). We further confirmed this in aging cohorts of *APP* TgCRND8 (TG) mice relative to nontransgenic (NonTG) age-matched mice (**Fig. 1a; Table EV1**). It is notable that increasing plaque burden, and not necessarily age, seems to be associated with increased Abi3 expression (**Fig. 1a**). In *MAPT* transgenic rTg4510 mice, the RNA levels of Abi3 increased in 4.5 month old tau expressing mice but reduced to levels comparable to NonTG littermates at 6 months (**Fig. 1b; Table EV2**).

To further evaluate Abi3 expression, we used RNAscope to localize Abi3 expression in mouse and human tissues (**Fig. 1c-j, Fig. EV1**). In AD patients, we observed Abi3 transcript in Iba1immunopositive microglia abutting A β plaques (**Fig. 1c; Fig. EV1a-c**). Interestingly, we also observed Abi3 transcripts in Iba-1 nonreactive cells in the grey matter, which are presumed to be neurons based on size and location (**Fig. EV1d-f**). Specificity for the RNA in situ hybridization signal was confirmed by using brain tissue from *APP* mice completely lacking the *Abi3* locus (Fig. 1e-f; Fig. EV1g-l). In 6 month old *APP* TgCRND8 mice, we observed Abi3+ microglia around A β deposits in the cortex (Fig. 1g; Fig. EV1m-n) and in the white matter tracts (Fig. EV1o). Similar to human cases, we also noted Abi3+ cells in the neuronal layers in the cortex and hippocampus (Fig. 1h; Fig. EV1p-r). Microglia in close proximity of A β plaques showed increased levels of Abi3 RNA in these TG mice (6 month old) (Fig. EV1m-o). We observed increased Abi3 positivity in A β plaque-associated microglia in 18 month old CRND8 mice (Fig. 1i; Fig. EV1s-u). These older mice also showed Abi3 RNA in forebrain neurons (Fig. 1j; Fig EV1u, x).

ABI3 and GNGT2 genes are co-regulated in APP mouse models and in AD

To elucidate how Abi3-specific immune signaling contributes to the neurodegenerative cascade process, we obtained the $Abi3^{-/-}$ mice from Jax Labs (Stock #028180). While using bulk RNAseq to characterize these mice, we serendipitously discovered that the levels of another gene, *Gngt2*, was dramatically reduced to the same extent as Abi3 (**Fig. EV2a**). We surveyed the gene maps and found that mouse Abi3 locus overlaps with two other genes on chromosome 11 – microglia-specific G protein gamma transducing activity polypeptide 2 (*Gngt2*) and *Phospho-1* (**Fig. EV2b**). We also confirmed that in humans, the arrangement of the *ABI3*, *GNGT2* and *PHOSPHO-1* genes is conserved, albeit on chromosome 17. Using data from UCSC genome browser, we discovered that the Velocigene targeted deletion in the *Abi3* locus knocked out both *Abi3* and *Gngt2* (**Fig. EV2b**). In subsequent sections, we will refer to these mice as Abi3-Gngt2'-. Notably, we did not find any changes in Phospho-1 levels in these mice.

Given that *Abi3* and *Gngt2* genes are overlapping, we hypothesized that their expression could be correlated. Using RNAseq data from the AMP-AD consortium, we investigated the concordance between the expression patterns of *Abi3* and *Gngt2*. We found that *ABI3* and *GNGT2* genes were co-regulated in three distinct AD patient cohorts: temporal cortex samples of Mayo Clinic AD cohort (Mayo TCX: $\rho = 0.644$, p = 2.2e-16) (**Fig. 2a**), cerebellar samples of Mayo Clinic AD cohort (Mayo CER: $\rho = 0.556$, p = 2.2e-16) (**Fig. 2b**) and Religious Orders Study and Rush Memory and Aging Project AD cohort (ROSMAP; $\rho = 0.328$, p = 2.2e-16) (**Fig. 2c**). We also confirmed that Abi3 and Gngt2 genes are co-regulated in the *APP* transgenic TgCRND8 mice (**Fig. 2d**, $\rho = 0.625$, p = 7.31-06) and in *MAPT* transgenic rTg4510 mice (**Fig. 2e**, $\rho = 0.554$, p = 0.018). The NonTG littermates of these mice showed no correlation between *Abi3* and *Gngt2* expression. In addition, we investigated 96 additional mouse transcriptomic datasets (Al-Ouran et al., 2019, Wan et al., 2020) and in 26 cohorts, we found that *Abi3* and *Gngt2* were both differentially regulated. Among these 26 of these cohorts, *Abi3* and *Gngt2* expression changes were concordant in 24 studies (**Table EV3**), showing that these genes are consistently co-regulated across different mouse models and experimental cohorts. Collectively, these analyses show that expression of *ABI3* and *GNGT2* genes are in a tight co-expression network in AD and AD mouse models.

Loss of *Abi3-Gngt2* induces reactive gliosis and a glial gene signature typically associated with neurodegenerative proteinopathy

We evaluated baseline gliosis in the parental Abi3- $Gngt2^{-/-}$ line. Using Iba-1 immunohistochemistry, we found that at 3 months of age, the haploinsufficient Abi3- $Gngt^{+/-}$ mice showed reduced hippocampal microgliosis compared to mice with intact Abi3- $Gngt2^{+/+}$ alleles (p<0.01 in hippocampus) and Abi3- $Gngt2^{-/-}$ mice (ns association) (**Fig. 3a-c**). At 6 months of age, we noticed an interesting gene-dosage dependent dichotomy in microgliosis in the parental Abi3- $Gngt2^{+/-}$ lines. The haplo-sufficient Abi3- $Gngt2^{+/-}$ showed higher Iba-1 reactivity relative to Abi3- $Gngt2^{+/+}$ mice (p<0.05 in cortex) and Abi3- $Gngt2^{-/-}$ mice (p<0.01 in cortex and

p<0.05 in hippocampus) (**Fig. 3d-f**). There were no significant differences in microgliosis between the *Abi3-Gngt2*^{+/+} and *Abi3-Gngt2*^{-/-} mice at this age (**Fig. 3d-f**).

At 3 months of age, the parental Abi3- $Gngt2^{-/-}$ line had significantly higher astrocyte burden than the Abi3- $Gngt2^{+/+}$ (p<0.05 in cortex and hippocampus) or Abi3- $Gngt2^{+/-}$ mice (p<0.01 in cortex) (**Fig. 3g-i**). At 6 months of age, the astrocyte burden continued to remain elevated in the Abi3- $Gngt2^{-/-}$ mice relative to Abi3- $Gngt2^{+/+}$ mice (p<0.05 in cortex and hippocampus) and Abi3- $Gngt2^{+/-}$ mice (p<0.05 in hippocampus) (**Fig. 3j-I**). This shows that complete loss of function of the Abi3 locus results in early astrocytosis that persists as the mice age.

We performed bulk RNAseq from the forebrains of 3 month old *Abi3-Gngt2^{-/-}* mice (Fig. 4; Fig. EV3). The upregulated RNAs in the *Abi3-Gngt2^{-/-}* mice were predominantly microglia-specific, such as C-type lectin domain family 7 member A (Clec7a/Dectin 1), Macrophage Expressed 1 (Mpeg1), Natural resistance-associated macrophage protein 1 (Slc11a1/Nramp1) and Lymphocyte Antigen 86 (Ly86) and Olfactomedin-like 3 (Olfm13) (Fig. 4a-b). Downregulated RNAs included Abi3, Gngt2, G Protein-Coupled Receptor 179 (Gpr179) and TNF Receptor Superfamily Member 1B (Tnfrsf1b) (Fig. 4a-b). Analysis of the Abi3-Gngt2^{+/-} mice relative to Abi3-Gngt $2^{+/+}$ mice revealed only one significantly altered (downregulated) gene -Protocadherin Gamma Subfamily A 5 (Pcdha5) - that is involved in establishing and maintaining intercellular connections in the brain (Fig. EV3a). Pathway analysis of the differentially expressed gene sets in Abi3-Gngt2^{-/-} mice vs Abi3-Gngt2^{+/+} mice revealed the involvement of immune pathways, such as granulocyte (GO:0071621) and leukocyte chemotaxis (GO:0030595), proliferation of mononuclear leukocytes (GO:0032943) and leukocyte-mediated immunity (GO:0002443) (Fig. 4c). The cell types most affected in Abi3-Gngt2^{-/-} mice were microglia $(p<0.05 \text{ relative to both } Abi3-Gngt2^{+/+} \text{ and } Abi3-Gngt2^{+/-})$ (Fig. 4d). There was a specific

reduction in neuronal gene counts in Abi3-Gngt2^{-/-} mice (p<0.01 relative to Abi3-Gngt2^{+/+}) and in Abi3-Gngt^{+/-} mice (p<0.001 relative to both Abi3-Gngt2^{+/+} and Abi3-Gngt2^{-/-}) (Fig. 4f). No significant changes in astrocyte or oligodendrocyte-specific gene expression were seen among the three groups (Fig. 4e, g). Surprisingly, the *Abi3-Gngt2^{-/-}* mice by itself showed induction of the amyloid/AD-associated PIG network, even in the absence of A β (p<0.01 relative to both Abi3-Gngt2^{+/+} and Abi3-Gngt2^{+/-} mice) (Fig. 4h). We also observed suggestive upregulated trends in the DAM, MGnD, ARM and A1 co-expression networks in the Abi3-Gngt2^{-/-} mice (Fig. 4i-l). Weighted gene co-expression network analysis (WGCNA) identified several gene modules correlating the *Abi3-Gngt2* genotype with the gliosis phenotype (Fig. 4n). The hub genes of selected modules that specifically correlated with the *Abi3-Gngt2^{-/-}* genotype and gliosis include Unc93b1 (antiquewhite2) and Immunoglobulin kappa variable 10-96 (coral2) (Fig. EV3b-g). Genes within the antiquewhite module were previously reported to be associated with gene signatures in AD, most notably DAM and MGnD (Keren-Shaul et al., 2017, Krasemann et al., 2017), PIG ((Deming et al., 2019) and homeostatic microglia (Krasemann et al., 2017) (Fig. **EV3h**). The antique white 2 module is especially relevant to AD pathophysiology as the module members, Ctss, Siglec h, Csf3r, Ly86 and C1qc, have been reported in both mouse models and humans (Walker, 2020). It was also highly associated with several immune and autoimmune conditions such as Staphylococcus infection and primary immunodeficiency as well as neurodegenerative diseases such as prion disease (Fig. 40). Overall, RNA-seq data shows upregulation of an immune activation gene expression profile corresponding to AD-typical gene expression patterns in *Abi3-Gngt2^{-/-}* mice, even in the absence of A β .

Reduction in Aβ levels in APP mice lacking Abi3-Gngt2

We then examined how complete insufficiency or haploinsufficiency of the Abi3 locus alters development of A^β plaques in APP transgenic CRND8 mice. Transgenic APP mice (referred as 'TG') that are wild type (+/+), haploinsufficient (+/-) or knocked out (-/-) for Abi3-Gngt2 genes were aged to 3 and 6 months and the A β levels assessed by immunohistochemistry and biochemical analysis (Fig. 5, Fig. EV4). There was no change in APP expression levels in these bigenic TG-Abi3-Gngt2 colonies (Fig. EV4a-b). In 3 month old TG-Abi3/Gngt2 lines, both Abi3-Gngt2^{+/-} (p<0.05) and Abi3-Gngt2^{-/-} (p<0.01) mice showed reduced AB plaques relative to littermate APP transgenic mice wild type for Abi3-Gngt2^{+/+} (Fig. 5a-b). Concurrently, there was a non-significant reduction in the number of Thioflavin S cored plaques in the TG-Abi3-Gngt2^{-/-} mice (Fig. 5c-d). Biochemical analysis showed significant reduction of FA associated insoluble Aβ42 and Aβ40 levels in both TG-Abi3-Gngt2^{+/-} (Aβ42: p<0.01; Aβ40: p<0.05) and TG-Abi3- $Gngt2^{-/-}$ (AB42: p<0.001; AB40: p<0.05) mice relative to littermate TG-Abi3-Gngt2^{+/+} mice (Fig. 5e-f). In the SDS detergent soluble fraction, both Aβ42 and Aβ40 values were reduced in TG-Abi3-Gngt2^{-/-} mice (p<0.05) while only Aβ42 was significantly reduced in TG-Abi3-Gngt2^{+/-} mice (p<0.05) relative to littermate TG-Abi3-Gngt2^{+/+} mice (Fig. 5g-h). We did not observe major changes in ubiquitin labeling of the A β plaques across all the *Abi3* genotypes (**Fig. EV4c**).

In 6 month old TG-*Abi3-Gngt2* lines, complete deletion of the locus resulted in reduced total A β plaque burden (**Fig. 5i-j**, p<0.05) as well as number of cored plaques (**Fig. 5k-l**, p<0.01). Notably, though the immunohistochemical plaque burden was similar between TG-*Abi3-Gngt2*^{+/-} and TG-*Abi3-Gngt2*^{+/+} mice (**Fig. 5i-j**), the former group showed lower thioflavin S (ThioS) plaque number compared to the latter group (**Fig. 5k-l**, p<0.05). The FA and SDS level of A β was mostly equivalent among all the groups except for reduction in SDS-associated A β 40 in TG-

Abi3-Gngt2^{-/-} mice relative to TG-*Abi3-Gngt2^{+/+}* mice (**Fig. 5m-p**, p<0.05). The patterns of ubiquitin staining around plaques appeared unchanged across the *Abi3* genotypes (**Fig. EV4d**).

We generated an additional cohort of 9 month old TG-*Abi3-Gngt2*^{+/-} mice for neuropathological comparisons with age-matched TG-*Abi3-Gngt2*^{+/+} mice. We found no changes in A β burden, astrocytosis (GFAP), microgliosis (Iba-1 and cd11b) or ubiquitin staining patterns between these two cohorts of mice at this age (**Fig. EV4e-m**).

Alterations in gliosis, especially astrocyte dysfunction, impacts synaptic health (Liu et al., 2018). To survey how amyloid plaques and gliosis in this model affect neuronal health, we evaluate several pre- and post-synaptic proteins in the 3 month time point. Consistent with the reduction in A β levels, we saw improved synaptic function as exemplified by increased synaptophysin level in both TG-*Abi3-Gngt2*^{+/-} mice (p<0.05) and TG-*Abi3-Gngt2*^{-/-} mice (P<0.01) (**Fig. EV5a-b**). We observed an insignificant trend in increased PSD95 levels in TG-*Abi3-Gngt2*^{-/-} mice while levels of synaptogyrin3 and spinophilin were unaltered in the three genotypes rested (**Fig. EV5c-h**). There was a reduction in vGlut1 (p<0.01 in TG-*Abi3-Gngt2*^{+/-}; p<0.05 in TG-*Abi3-Gngt2*^{-/-}), GluR1 (p<0.05 in TG-*Abi3-Gngt2*^{+/-}) and GluR2 levels (ns trend in TG-*Abi3-Gngt2*^{-/-}), signifying dysfunctional glutamatergic signaling (**Fig. EV5i-n**).

Immunohistochemical and RNAseq shows gene dose-dependent upregulation of inflammatory profile in TG-*Abi3-Gngt2^{-/-}* mice

Aβ levels are generally well-correlated with immune activation indicated by microgliosis and astrocytosis (Kinney et al., 2018). Consistent with this idea, we predicted lower burden of microglia (Iba-1 immunoreactivity) and astrocytes (GFAP immunoreactivity) in TG-*Abi3-Gngt2*^{-/-} mice that showed robust Aβ reduction at 3 months and 6 months of age. Surprisingly, we found

that at both ages, the TG-Abi3-Gngt2^{-/-} mice showed similar levels of Iba-1 reactive microgliosis compared to TG-Abi3-Gngt2^{+/+} mice (3 months: Fig. 6a-c; 6 months: Fig. 6d-f). TG-Abi3-Gngt2^{+/-} mice showed decreased cortical microglia at 3 months compared to TG-Abi3-Gngt2^{-/-} mice (Fig. 6a-c; p<0.05), but this normalized to equivalent levels by 6 months of age (Fig. 6d-f). The patterns of astrocyte burden reflected a differential scenario across the three *Abi3* genotypes. At 3 months of age, the TG-Abi3-Gngt2^{+/-} mice had significantly lower astrocytosis compared to both TG-Abi3-Gngt^{+/+} (p<0.01 in cortex; p<0.001 in hippocampus) and TG-Abi3-Gngt2^{-/-} mice (p<0.001 in cortex; p<0.01 in hippocampus) (Fig. 6g-i). At 6 months of age, these differences normalized in the cortex but hippocampal GFAP burden in TG-Abi3-Gngt2^{+/-} mice was higher than both TG-Abi3-Gngt^{+/+} or TG-Abi3-Gngt2^{-/-} mice (Fig. 6j-l). There was no significant difference in astrocytosis burden between the TG-Abi3-Gngt^{+/+} or TG-Abi3-Gngt2^{-/-} mice in 3 month or 6 month old cohorts (Fig. 6g-i, 6j-l), indicating that reduction of Aβ did not ameliorate the existing astrocytic phenotype inherent in the Abi3-Gngt2 line. Overall, the immunohistochemistry data suggests a biphasic age-dependent response of the astrocytes and microglia in APP mice to Abi3-Gngt2 gene dosage.

We performed bulk RNAseq from the forebrains of 3 month old TG-*Abi3-Gngt2* mice (**Fig. 7**, **Fig. EV6**). Relative to the *TG-Abi3-Gngt*^{+/+} mice, the *TG-Abi3-Gngt2*^{-/-} mice showed lower Abi3 and Gngt2 as expected (**Fig. 7a-b**). Other genes that were down-regulated in the *TG-Abi3-Gngt2*^{-/-} mice are *Adgrf3* (Adhesion G Protein-Coupled Receptor F3), *S100a8* and *S100a9* (S100 Calcium Binding Protein members A8 and A9). Among the genes that were upregulated in these mice were *Gm7879* (Peptidylprolyl isomerase H), *Aklr1c13* (Aldo-keto reductase family 1 member C13), *Fndc9* (Fibronectin Type III Domain Containing 9), tetraspanin *Cd9* and Lymphocyte antigen *Ly86* (**Fig. 7a-b**). The molecular pathways represented by gene expression

changes in TG-Abi3-Gngt2^{-/-} mice include syncytium formation, cellular fusion, calcium mediated signaling and extracellular matrix organization (Fig. 7c), recapitulating expected functional properties of the ABI family members (Mendoza, 2013). Additional pathways that were enriched were gliogenesis (GO:0014015) and response to LPS (GO:0034189), consistent with altered glial homeostasis. We did not observe any significant gene expression changes in TG-Abi3-Gngt2^{+/-} mice relative to TG-Abi3-Gngt^{+/+}mice (Fig. EV6a). In the TG-Abi3-Gngt2^{-/-} mice, most of the gene expression changes were indicative of increased microglial (p<0.05 relative to TG-Abi3-Gngt2^{+/-}) and astrocytic involvement (p<0.01 relative to TG-Abi3-Gngt2^{+/-}; p<0.05 relative to $TG-Abi3-Gngt^{+/+}$) (Fig. 7d-e), with no changes observed in neuronal and oligodendrocyte-specific gene expression (Fig. 7f-g). Surprisingly, we found that in spite of reduced Aβ plaques, TG-Abi3-Gngt2^{-/-} mice showed gene signatures typically identified in AD tissues or preclinical models of AD. These mice showed upregulated PIG (p<0.05 relative to TG-Abi3-Gngt2^{+/-}; p<0.05 relative to TG-Abi3-Gngt^{+/+}) (Chen et al., 2020), DAM (p<0.05 relative to TG-Abi3-Gngt2^{+/-}) (Keren-Shaul et al., 2017), MGnD (p<0.05 relative to TG-Abi3-Gngt2^{+/-}) (Krasemann et al., 2017) and A1 astrocyte (p<0.05 relative to TG-Abi3-Gngt^{+/+}) (Liddelow et al., 2017) gene profile signatures (Fig. 7h, i, j, l). We did not detect any selective induction of either the ARM (Sala Frigerio et al., 2019) or A2 astrocyte (Liddelow et al., 2017) phenotypes in the three TG-Abi3/Gngt2 genotypes (Fig. 7k,m). Notably, most of these modules (PIG, DAM and MGnD) are driven by Apoe, Tyrobp and Trem2 while the ARM signature is driven by specialized microglial subgroups overexpressing MHC type II genes. WGCNA identified several gene co-expression modules that allowed us to correlate neuropathological traits to cell types (Fig. 7n), GO pathways (Fig. 7o), hub genes (Suppl. Fig. EV6b-g) and AD gene expression signatures (Suppl. Fig. EV6h). Modules that were positively correlated with the Abi3-Gngt2

genotype but were negatively correlated with AB biochemical levels or AB plaque burden included honeydew1 and plum3. These gene modules were primarily driven by microglia- and astrocyte-specific genes, respectively. We identified hub genes that regulate these different gene network modules (Fig. EV6b-e). Notably, Chill/Chi3ll/YKL-40 (Chitinase-like 1) that is the top hub gene in honeydew1 is related to inflammation and AD pathophysiology (Llorens et al., 2017). The top hub gene in the plum3 module – Interferon Regulatory Factor 8 (Irf8) – correspond to interferon signaling that has recently been identified to be upregulated in microglia from human AD (Zhou et al., 2020). This module is especially enriched for immune function, with the cd37 hub gene related to a Tyrobp-regulated microglial module in AD (Zhangi et al., 2013) and Lat2 identified as a core transcriptional signature of AD microglia (Patir et al., 2019). Conversely, modules negatively correlated with the *Abi3-Gngt2* genotype but were positively correlated with $A\beta$ biochemical levels or $A\beta$ plaque burden was sienna3 which included a mixture of astrocyte and endothelial genes (Fig. 7n, Fig. EV6f-g). Among these co-expression modules, we found that the plum3 module corresponds to homeostatic microglia signature (Fig. EV6h). Overall, RNAseq and immunohistochemical data shows both amyloid-independent and amyloid-dependent dysfunctional immune signature in the *Abi3-Gngt2^{-/-}* mice.

Exacerbated ptau accumulation in *Abi3-Gngt2^{-/-}* mice expressing human mutant tau

Because of the inherent dysfunctional immune milieu and early astrocytosis in the parental *Abi3-Gngt2^{-/-}* mice, we decided to test how this would affect the development and progression of tauopathy. We used recombinant AAVs to deliver the pro-aggregant P301L/S320F human tau, WT human tau or a control vector in neonatal *Abi3-Gngt2^{-/-}* mice or *Abi3-Gngt2^{+/+}* C57BL/6 mice (Beckman et al., 2021, Koller, 2019) (**Fig. 8; Fig. EV7**). We examined mice at 3 months of age and 6 months of age. We first confirmed that the expression of tau transgene was equivalent

in P301L/S320F tau expressing *Abi3-Gngt2^{-/-}* and *Abi3-Gngt2^{+/+}* mice at 3 months (**Fig. 8a,b**) and 6 months (**Fig. 8g,h**). We did not find any human tau signal in the control vector injected *Abi3-Gngt2^{-/-}* mice or *Abi3-Gngt2^{+/+}* mice as expected (**Fig. 8a,b,g,h**). We noticed that the level of phosphorylated tau (ptau) and misfolded pretangle tau was significantly higher in 3 month old P301L/S320F tau expressing *Abi3-Gngt2^{-/-}* mice compared to *Abi3-Gngt2^{+/+}* mice (p<0.05 for CP13 and MC1 respectively) (**Fig. 8c,d,e,f**). None of the control injected mice showed any detectable ptau or misfolded tau at either age (**Fig. 8c-f, i-I**). We also confirmed the presence of frank neurofibrillary tangles (NFT) in P301L/S320F tau expressing 3 month old *Abi3-Gngt2^{+/+}* mice by staining with ThioS (**Fig. EV7a**) or by biochemical analysis of insoluble tau following sequential extraction of cell lysates (**Fig. EV7b-c**). At 6 months of age, the P301L/S320F tau expressing *Abi3-Gngt2^{-/-}* mice showed higher ptau immunoreactivity compared to *Abi3-Gngt2^{+/+}* mice (**Fig. 8i-j**; p<0.001), while the levels of pretangle tau were equivalent between the two groups (**Fig. 8k-I**).

We also examined the neuropathologies in human WT tau expressing Abi3- $Gngt2^{-/-}$ mice and Abi3- $Gngt2^{+/+}$ mice. In the 3 month old cohorts, we did not find any differences in the total tau levels or ptau levels of Abi3- $Gngt2^{-/-}$ and Abi3- $Gngt2^{+/+}$ mice (**Fig. EV7d-g**), nor did we see any induction of MC1-reactive pretangle tau (data not shown). In the 6 month old cohort, while the levels of tau expression were comparable (**Fig. EV7l-m**), we noticed considerably higher ptau levels in Abi3- $Gngt2^{-/-}$ mice relative to Abi3- $Gngt2^{+/+}$ mice (p<0.0001) (**Fig. EV7n-o**). Overall, loss of Abi3-Gngt2 resulted in increased ptau in two separate tau cohorts.

Astrocyte activation following tau overexpression in *Abi3-Gngt2^{-/-}* mice

We wanted to examine whether the inherent immune phenotype in *Abi3-Gngt2^{-/-}* mice would be exacerbated in the presence of ptau (**Fig. 9**). In 3 month old mice, P301L/S320F tau expression

had a robust microglial response in the *Abi3-Gngt*^{+/+} mice (p<0.01 relative to control vector; p<0.05 relative to tau expressing *Abi3-Gngt2*^{-/-} mice) (**Fig. 9a-b**). At 6 months of age, the P301L/S320F tau expressing *Abi3-Gngt2*^{-/-} mice showed higher microglial response than the rest of the cohorts (p<0.01 relative to control vector) (**Fig. 9c-d**). In WT tau expressing mice, we observed an identical age-dependent pattern for microgliosis with highest levels of microgliosis in 6 month old *Abi3-Gngt2*^{-/-} mice (**Fig. EV7j, k, r, s**).

In the 3 month old and 6 month old P301L/S320F tau expressing *Abi3-Gngt2^{-/-}* mice, we observed higher astrocytosis concordant with increased pathological tau accumulation (**Fig. 9e-h**). P301L/S320F tau expressing *Abi3-Gngt2^{-/-}* showed higher GFAP burden relative to control vector (p<0.0001) as well as P301L/S320F tau expressing *Abi3-Gngt2^{+/+}* mice (p<0.001) at both ages. Thus, the astrocytic response was more consistent with the neuropathology at both ages. This data also reveals an interesting dichotomy in the response of astrocytes and microglia to pathological tau, especially at the younger age examined (**Fig. 9b** vs **Fig. 9f**). In 3 month old WT tau expressing mice, astrocytosis immunoreactivity was more enhanced in *Abi3-Gngt2^{+/+}* mice than *Abi3-Gngt2^{-/-}* mice (p<0.05) (**Fig. EV7h-i**). At 6 months of age, however, we observed higher levels of astrocytosis in WT tau expressing *Abi3-Gngt2^{-/-}* mice compared to *Abi3-Gngt2^{+/+}* mice (**Fig. EV7p-q**; p<0.01). This implies an age-dependent as well as neuropathology dependent immune phenotype induced by tau overexpression in the *Abi3-Gngt2^{-/-}* mice.

AD-associated mutation alters ABI3 phosphorylation

To understand the differences between wild type and AD-associated S209F ABI3, we overexpressed C terminal FLAG tagged recombinant constructs in HEK293T cells. C terminally FLAG tagged ABI3 has been previously shown to be functionally active (Sekino et al., 2015).

We detected ABI3 protein using either anti FLAG antibody, an in-house antibody raised against S209 ABI3 or a N terminal ABI3 antibody (Millipore Sigma). We observed that wild type ABI3, but not S209F ABI3 migrated as a double band (**Fig. 10a**) which is consistent with data reported earlier (Sekino et al., 2015). To confirm that the band migrating on the top is a phosphorylated form, we incubated wild type ABI3 or S209F ABI3 transfected HEK293T cell lysates with Lambda Protein Phosphatase. Incubation with Lambda Protein Phosphatase at 30°C but not at 4°C abolished the upper band in wild type ABI3 lysate (**Fig. 10b**). Mutating the Phenylalanine (F) at position 209 to dephospho-mimetic Alanine (A) or phospho-mimetic Aspartate (D) reverses this deficit in phosphorylation to levels that are comparable to WT ABI3 protein (**Fig. 10c-d**). This shows that presence of phenylalanine at position 209 specifically impairs overall ABI3 phosphorylation, though auto-phosphorylation at this site is not necessary. Since, phosphorylation of Abi family of proteins is related to their stability and function (Huang et al., 2007), this would imply that the Ser to Phe mutation could render the ABI3 protein functionally inactive.

Discussion

The mechanism through which ABI3 alters risk for AD remains uncertain. Here we document that Abi3, though primarily expressed in microglia, is also expressed in other cells in human and mouse brain. Age-associated increases in Abi3 mRNA appear to be largely attributable to local increases in A β plaque-associated microglia. Characterization of an *Abi3^{-/-}* mouse strain identified that the overlapping gene Gngt2 is also knocked out. We conducted additional studies to demonstrate that *Abi3* and *Gngt2* expression are tightly co-regulated in both mice and humans. Using this *Abi3-Gngt2^{-/-}* mice, we show that loss of the Abi3-Gngt2 expression predisposes the mice to an immune phenotype characterized by reactive gliosis and gene expression patterns

resembling an AD-associated profile. Notably in these mice, the AD/neurodegenerationassociated genes Trem2, Plcg2, Tyrobp and Csf1r are upregulated, even in the absence of $A\beta$. We find that the loss of *Abi3-Gngt2* locus has opposing effects on amyloid and tau pathology in mice. Loss of this locus results in a reduction in amyloid pathology and preservation of synaptic markers, though effects on amyloid are diminished as the mice age. In contrast, we noted that loss of *Abi3-Gngt2* markedly increases tau pathology (Fig. 11). Because Abi3 is expressed in neurons as well as microglia, it is possible that the effect of Abi3-Gngt2 on A β and tau could be modulated by glial as well as neuronal signaling pathways. Our experimental models, whereby we observed functional dichotomy in Abi3-mediated immunoproteostasis in Aß and tau models, allows us to impute the probable function of the risk variant in influencing AD risk. If, for example, the detrimental effect of S209F Abi3 is mediated by increasing A β , then the diseaseassociated mutation is expected to reinforce additional functional characteristics. On the other hand, if the effect is cell autonomous, leading to deregulation of microglial surveillance activity or exacerbating neuronal tauopathy, then the mutation could be mimicking a loss of function phenotype. Indeed, examples of such context-dependent manifestations can be found in Trem2 models, where depending on the disease stage, neuropathology and gene dosage, Trem2 expression (or lack of) recapitulates a partial loss-function or demonstrates additional pathological characteristics (Bemiller et al., 2017, Lee et al., 2021, Leyns et al., 2017, Sayed et al., 2018).

Taken together, our data show that a dysfunctional immune environment accompanying the lack of *Abi3-Gngt2* is associated with a dichotomous effect on A β and tau proteinopathy. Indeed, manipulation of expression of Trem2, Tyrobp, Cx3cl1/Cx3cr1, IL1 β and IFN- γ have all been shown to have opposing effects on amyloid and tau pathologies (Audrain et al., 2019, Chakrabarty et al., 2010, Haure-Mirande et al., 2019, Jay et al., 2015, Lee et al., 2021, Leyns et al., 2017, Li et al., 2015, Meiland et al., 2020, Parhizkar et al., 2019, Sayed et al., 2018). We have previously referred to this multi-directional relationship between immunity and AD-type proteinopathy as immunoproteostasis (Chakrabarty et al., 2015, Golde, 2019). Harnessing the immune system as a potential treatment for AD remains attractive. Our current data, however, highlights the challenges of harnessing immunoproteostasis to treat AD as such therapies could theoretically have opposing effects of AD-triggering neurodegenerative proteinopathy and exacerbate underlying brain organ dysfunction.

A recent study, using a bigenic model of 5xFAD and $Abi3/Gngt2^{-/-}$ mice, reported increased A β plaques at 8 months of age and an inflammatory gene expression signature similar to our data (Karahan et al., 2021). However, this report could not specifically attribute the DAM profile to Abi3/Gngt2 genotype (Karahan et al., 2021). While the changes in A β proteinopathy is opposite of what we have observed, this could be due to this group using a single time point and a mouse model expressing both mutant *APP* and *PS1* genes. Whether *Abi3/Gngt2* could have an additional interaction with PS1-related phenotype remains to be studied. Research groups have reported disparate observations in mouse models of neurodegenerative proteinopathies that undergo immune manipulations. A recent example is when the profound systemic and neural inflammation inherent in the c9orf72 deficient mice was found to be reversed when maintained in a different mouse facility (Burberry et al., 2020). In fact, immune-related phenotypes, as inherent in this Abi3/Gngt2-/- mice, are extremely sensitive to environmental factors and local immune stressors that can regulate the microbiome (Erny et al., 2015).

Our study highlights the utility of detailed transcriptomic analysis in phenotyping new disease models. During our study, we found that the *Gngt2* gene, whose putative promoter region and a

non-coding exon of one transcript isoform overlaps with the *Abi3* locus, is also lost in this velocigene knockout model. Gngt2 is reported to be a microglia-specific gene and is involved in cone phototransduction (Ong et al., 1997). To establish the physiological relevance of this dual knock-out, we used extensive informatics analysis from human and mice showing that ABI3 and GNGT2 are co-regulated, indicating that these two genes exist in a co-expression network. While the original exome analysis data (Sims et al., 2017) did not find any AD risk related to *GNGT2*, a newer study identified GNGT2 as one of the 989 genes that mapped to the 38 genomic loci related to AD risk (Wightman et al., 2021). Future studies should dissect out the specific functions of the genes resident in the *ABI3* locus.

Our study is an exemplar for highlighting how immune function can be differentially related to development and progression of AD-typical neuropathologies. Several seminal studies have shown that microglia-mediated immune activation can exacerbate both A β and tau pathologies (Friker et al., 2020, Heneka et al., 2013, Ising et al., 2019). More recently however, immune activation has been shown to have disease stage-dependent outcome. Studies in human patients support this notion of a dichotomous role of inflammation, where data indicates that early inflammation may play a protective role in prodromal AD phase (Fan et al., 2017, Hamelin et al., 2016) but that chronic age-associated inflammation may be overwhelmingly detrimental. This dichotomy of immunity having a beneficial as well as a harmful effect has been shown previously for at least two other immune factors in mice. Hippocampal expression of IL-1 β was shown to robustly reduce plaques in the APP/PS1 model and 3xTg-AD model but worsened tauopathy in the 3xTg-AD model (Ghosh et al., 2013, Shaftel et al., 2007). Similarly deficiency of Cx3cr1 reduced amyloid deposition in two different *APP* models but aggravated tau hyperphosphorylation in hTau mice (Bhaskar et al., 2010, Lee et al., 2010). More recently, this

dichotomy has been elegantly demonstrated in multiple models of Trem2 and Tyrobp (Audrain et al., 2019, Haure-Mirande et al., 2019, Jay et al., 2015, Lee et al., 2021, Leyns et al., 2017, Meilandt et al., 2020, Parhizkar et al., 2019, Sayed et al., 2018). Our previous data (Chakrabarty et al., 2010, Li et al., 2015), as well as our current data, also indicates that immune function can have distinctive effects on $A\beta$ and tau, a paradigm that we have referred to as immunoproteostasis (Golde, 2019). The outcomes of *Abi3-Gngt2* related immunoproteostasis was based on age as also on gene dose, consistent with studies on Trem2 models of AD (Meilandt et al., 2020, Sayed et al., 2018). Combined, our data shows that underlying genetic factors that enhance the reactivity of immune cells might result in early beneficial effects on $A\beta$ but this might adversely affect emergence of tauopathy and age-progressive $A\beta$ pathology. Thus, designing immune-based therapies warrants cautious deliberation with careful consideration of disease stage and immune mediator function.

Understanding how immunoproteostasis is modified by brain neuropathology and age is important as this is expected to modify the efficacy of immune-based therapies. For amyloid pathology, there is data that activated micro/astroglia enhances A β phagocytosis (Chakrabarty et al., 2010, Chakrabarty et al., 2010a, Shaftel et al., 2007), which is a desired outcome, but why that glial activation state appears to be associated with enhanced tau pathology remains enigmatic. Given that large number of immune signaling pathways are altered in our current study and in previous studies on AD immunoproteostasis (Heppner et al., 2015), it will be challenging to gain more detailed mechanistic insights. Indeed, it may not be a single pathway or factor that results in these age- and pathology-related dichotomous outcomes but the combined action of many different signaling alterations on A β and tau. Given that alterations in immune signaling induced by amyloid deposition are a clear hallmark of AD, such data provide an alternative, but not mutually exclusive, mechanisms for spreading of tau pathology. Indeed, signaling initiated by microglia or astrocytes in response to amyloid deposition could then trigger induction of tau pathology. Such signaling could explain the apparent crosstalk between amyloid and tau (Nisbet et al., 2015), characterized by the unique region-specific spread of tau and could explain the temporal lag between amyloid deposition and tau tangle formation in humans.

Analysis of co-expression networks reveals interesting transcriptomic differences in parental Abi3-Gngt2^{-/-} lines and the TG-Abi3-Gngt2^{-/-} lines. While the parental Abi3-Gngt2^{-/-} lines mostly indicated an abundance of immune signature, the TG-Abi3-Gngt2^{-/-}mice showed additional signatures consistent with the known functions of the ABI family of proteins (Mendoza, 2013). Consideration of these functions - calcium mobilization, extracellular matrix reorganization and intercellular communication (Siddiqui et al., 2012) - will be important in understanding AD pathogenesis in addition to the involvement of more well-characterized phagocytotic and debris removal functions of microglia. Indeed, a recent study suggests that Abi3-Gngt2^{-/-} microglia exhibits reduced surveillance of brain parenchyma (Simonazzi, et al., 2021). In terms of the hub genes identified in our study, Chi311/YKL-40 is singularly important as it is correlated with the Abi3-Gngt2 genotype in our study. YKL-40 is primarily an astrocytic protein that is elevated in AD and is considered a potential biomarker (Craig-Schapiro et al., 2010). Recently YKL-40 has been shown to have non cell autonomous activity in the brain, affecting microglial function, circadian clock and generally AD progression (Lananna et al., 2020). How Abi3 plays a role in AD neuropathologic cascade by modulating YKL-40 function remains an untested possibility.

ABI3 has been imputed to be of microglial origin (Patir et al., 2019). A previous study has reported clusters of ABI3 immunopositive microglia localized around A β deposits in AD patients (Satoh et al., 2017). Our in situ hybridization data indicates that ABI3 is present in both

microglia and neurons. We also show that the amount of ABI3 RNA increases in concordance with A β deposits. Because Abi3 is present in both neurons and microglia, its role in non-cell autonomous and cell autonomous signaling in AD proteinopathy and disease progression could be equally important. Our unexpected finding of neuronal ABI3 is reminiscent of the observations on PLCG2, which was initially thought to be myeloid cell-specific, but its RNA was also found in neurons and endothelial cells (Magno et al., 2019). PLCG2, like ABI3, was identified as an AD protective factor using exome analysis strategies (Sims et al., 2017). Given that protein levels in any specific cell cannot always be inferred from RNA levels (Liu et al., 2016), some caution is warranted here before confirming our in situ observations by protein detection methods.

The ABI family of proteins, especially ABI-1 and ABI-2, are involved in cytoskeletal reorganization (Mendoza, 2013). The function of ABI3, much less S209F ABI3, in the brain is unknown. Some previous studies have reported ABI3 in microglia with ramified or amoeboid morphology (Patir et al., 2019, Satoh et al., 2017). Another recent paper showed that absence of Abi3 (using the same models as used in this study) alters microglial morphology and curbs its function in homeostatic surveillance (Karahan et al., 2021, Simonazzi et al., 2021). This would be consistent with the previously documented role of ABI3 in regulating cytoskeletal dynamics (Bae et al., 2012b, Ichigotani et al., 2002).

The *Abi3-Gngt2^{-/-}* mice also show increased Trem2, Tyrobp and Plcg2, which would be consistent with cooperativity between different AD-associated risk factors. In fact, we observed this early immune activation in the absence of A β , which could illuminate how underlying genetic risk factors could cross-talk to prime the aging brain, even before the frank appearance of proteinopathy. Cross-talk between AD risk immune genes has been recently demonstrated,

notably between Cd33 and Trem2 (Griciuc et al., 2019). The TG-Abi3-Gngt2-/- mice also over time showed dysfunctional immune phenotype, with age-dependent reduction of beneficial effect on A β and accumulation of ptau. Overall, this would suggest that loss of *Abi3-Gngt2* function leads to early induction of immunity that could lead to detrimental outcomes in the longer term (**Fig. 11**). It is known that phosphorylation is key to maintaining the stability and function of ABI family of proteins (Courtney et al., 2000, Mendoza, 2013). Thus, our data showing that the ADassociated mutation results in hypomorphic function or partial loss of function. Based on our data, it is tempting to suggest that wild type ABI3 could suppress immune gene expression and modulate the cross-talk between different AD immune risk factors that is normally associated AD progression and possibly lead to a beneficial outcome (**Fig. 11**).

Materials and Methods

Mice. All animal studies were approved by the University of Florida IACUC and recombinant DNA use was approved by University of Florida EH&S Office. In this study, we have created several lines of new transgenic *APP* mouse models that are deficient in Abi3. We obtained live *Abi3*(+/-) mice on a BL/6 background from Jax Labs (B6N(Cg)-Abi3tm1.1(KOMP)Vlcg/J; Stock #028180). *Abi3*(+/-) mice were bred to TgCRND8 mice (*APPswe/ind*) (Janus et al., 2000), maintained on BL/6xC3H background, which were then crossed with *Abi3*(-/-) to generate the three different *Abi3* genotypes (wild type: +/+; heterozygous +/-; knock-out: -/-) with the *APP* transgene. Mice were healthy and without any obvious phenotype, except sudden death of 25% of *APP* transgenic mice (as observed in parental TgCRND8 mice). Mice were maintained on food and water ad libitum on a 12 hour light/dark cycle. All animals were euthanized following IACUC-approved procedures, with AAV expressing animals additionally being perfused intracardially post mortem with cold saline. Brains were collected immediately, with left hemisphere

flash frozen and right hemisphere drop-fixed in 10% normal buffered formalin. The sex distribution of each cohort is indicated in the figures (open or closed circles) or indicated in figure legends.

Human tissue specimens. Formalin-fixed, paraffin embedded brain tissue samples of deidentified patients with AD and normal control subjects were provided by the University of Florida Neuromedicine Human Brain and Tissue Bank (UF HBTB) following institutional regulations.

AAV production and neonatal injection. Recombinant AAV was produced and injected in neonatal mice on day P0 as described earlier (Chakrabarty et al., 2013). Specifically, an AAV construct expressing the 0N/4R human tau construct under the control of CBA promoter (Koller, 2019) was packaged in capsid serotype 1 for these experiments. Control mice were injected with an empty vector (AAV vector backbone CTR0 packaged in serotype 1). All animals were injected with $2\mu l$ (1x10¹⁰ vector genomes) of AAV1 in the cerebral ventricles of each hemisphere as described before (Chakrabarty et al., 2013).

Biochemical extraction of proteins from brain. Frozen forebrains (without cerebellum or olfactory bulbs) were cryopulverized and split into two groups for *APP* mice, one for Aβ analysis and another for RNA analysis. All ultracentrifugation was done in a Beckman Optima TLX centrifuge with a fixed angle TLA55 rotor. All lysates were prepared to a final concentration of 1ml/150mg of dry tissue. The first aliquot was weighed on dry ice and added to RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.5% Deoxycholate, 0.1%SDS, 1x protease inhibitor cocktail). Tissues were homogenized using Tissue Master (Omni International Tissue Master 125) for 30 seconds. Tissue homogenate were centrifuged at 43,000 rpm for 1 hour at 4 °C. Supernatant was aliquoted and stored at -80 °C as the RIPA lysate. The residual pellet was

resuspended in 2% sodium dodecyl sulfate (SDS), sonicated with 3 bursts of 1 minute each (Misonix Q700), and then centrifuged at 43,000 rpm for 1 hour at 15 °C. The supernatant was aliquoted and stored at -80 °C as the SDS lysate. The pellet was resuspended in 70% formic acid (FA), sonicated, centrifuged at 43,000 rpm at 15 °C, and the supernatant stored at -80 °C as the FA lysate.

For AAV-injected brain, the brains were cryopulverized and extracted using tau-specific buffer conditions as described before (Koller, 2019). Briefly, brains were homogenized (Omni International) in appropriate amount of TBS buffer (50mM Tris base, 274 mM NaCl, 5 mM KCl, pH 8) containing protease and phosphatase inhibitors (Pierce Protease & Phosphatase Inhibitor Mini Tablets, ThermoScientific). Following centrifugation at 22,000 rpm for 20 minutes at 4 °C in a Beckman ultracentrifuge, supernatant was stored at -80 °C as S1. The pellet, P1, was resuspended in high salt buffer (10mM Tris base, 0.8M NaCl, and 10% Sucrose) containing 0.05% Triton x-100 (Fisher) and protease and phosphatase inhibitors (Pierce Protease & Phosphatase Inhibitor Mini Tablets, ThermoScientific) and separated at 22,000 rpm for 20 min at 4 °C into S2 and P2. Pellet P2 was resuspended in 1% sarkosyl, incubated at 37 °C for one hour with intermittent gentle shaking and separated at 60,000 rpm for 1hr at 15 °C into S3 and P3. Pellet P3 was resuspended in urea/SDS buffer (4M urea, 2% SDS, and 25mM Tris HCl, pH 7.61) by sonicating (Misonix sonicator) and separated at 50,000 rpm at 15 °C for 30 min. The resulting supernatant S4 was designated as insoluble NFT tau.

Immunohistochemical and histological analysis. Formalin fixed brains were paraffin embedded, and used for analysis. Slides were deparaffinized using standard procedure (described in (Koller, 2019)) and antigen retrieval performed with steam. Slides were blocked in 2% FBS in 1xPBS for 1 hour at room temperature followed by primary antibody incubation at 4 °C overnight (see

Table EV4). Appropriate secondary antibody (ImmPress reagents, Vector Labs) was used followed by detection using DAB (Vector Labs) and hematoxylin counterstaining. Slides were mounted in Permount mounting media. ThioS staining was done by incubating deparaffinized and rehydrated slides in 1% ThioS (see **Table EV4**) for 7 minutes at room temperature. Slides were quickly washed in 70% ethanol and then water and mounted with Fluoromount containing DAPI.

Analysis of Immunochemical and Histological Images. Images of stained slides were captured using Scanscope XT image scanner (Aperio, Vista, CA, USA) and percent area of immunostained slides was quantified with the Positive Pixel Count program (Aperio) that detects DAB staining. 3 section per brain was selected and quantified. Data is presented as % immunoreactivity ± sem and statistical comparisons were conducted using 1-Way ANOVA with a Tukey post hoc test, if necessary. Fluorescent images were captured using BZ-X710 All-in-one Fluorescence Microscope (Keyence Co., Itasca, IL). MC1 stained sections and ThioS stained sections were manually counted for the number of cells or plaques (respectively) positive for the stain.

Biochemical analysis of tissue lysates. Protein concentrations of RIPA, SDS (in *APP* mice) and S4 fractions (in AAV tau expressing mice) were determined using Bicinchoninic Acid assay (Pierce BCA Protein Assay Kit, ThermoScientific). 20-25 µg of RIPA or SDS lysate or 1 µg of S4 lysate were separated in a 4-20% Tris-glycine gel (Novex, Invitrogen) and transferred to PVDF membranes. Membranes were blocked for 1 hr in 0.5% casein and incubated overnight at 4 °C in primary antibody (see **Table EV4**). Membranes were incubated in appropriate secondary antibody (see **Table EV4**) diluted in 0.5% casein (1:20,000) with 0.005% SDS for 1 hour at room temperature. Membranes were washed in 1X TBS and water, and protein bands were

detected using the multiplex Li-Cor Odyssey Infrared Imaging system (Li-Cor Biosciences, Lincoln, NE, USA). Relative band intensity was quantified using ImageJ software (NIH).

For ELISA determination of A β levels, Immulon 4HBX plates were coated with 20µg/µl of capture antibody (**Table EV4**) overnight at 4 °C. Plates were washed and blocked in Block Ace (**Table EV4**) at 4 °C overnight. Plates were washed and loaded with SDS lysates or FA lysates (neutralized in Tris buffer) at predetermined dilutions (ranging from 1:300 for 3 month old mice to 1:750 for 6 month old mice). Following overnight incubation, plates were washed and incubated in capture antibody specific for A β 42 or A β 40. Following thorough washing, colorimetric assay was developed using TMB solution and detected using Spectramax ELISA reader. The data was analyzed using Softmax program.

RNA-seq and data analysis: RNA was extracted from frozen, pulverized forebrains using TRIzol reagent (Invitrogen). Extracted RNA was cleaned using RNeasy mini extraction kit with an oncolumn DNase treatment (Qiagen). RNA quality was quantified with the Qubit RNA HS assay (Invitrogen). RNA quality was checked on an Agilent Bioanalyzer 2100 with the Eukaryote Total RNA Nano chip (**Table EV4**). Total RNA (1 microgram) was used for sequencing library preparation using the Illumina TruSeq RNA library prep with polyA purification (**Table EV4**). Libraries were loaded at equimolar quantities and sequenced on paired-end, 75 bp runs on the Nextseq 500 (Illumina) with a goal of attaining a yield of 30-50 Mb of sequence per sample. RNA extraction and sequencing was performed with an aim to reduce batch effects. *RNA-seq data analysis.* FASTQ alignment, gene counts and differential expression analysis. FASTQ files were aligned against the mouse genome (GRCm38) and GRCm38.94 annotation using STAR v2.6.1a (Dobin, Davis et al., 2013) to generate BAM files. BAM files were used to generate gene counts using Rsamtools (Dani, Wood et al., 2018) and the summarizeOverlaps function with the GenomicAlignments package (Lawrence et al., 2013). Differential gene expression analysis was performed with DESeq2 package using the "DESeq" function with default settings (Love et al., 2014) which fits a generalized linear model for each gene. Subsequent Wald test p-values are adjusted for multiple comparisons using the Benjamini-Hochberg method (adjusted p-value). Pair-wise changes in gene expression levels were examined between groups to identify differentially expressed genes (DEGs). DEGs were defined as an absolute log2Fold Change \geq 0.5 and an adjusted p-value \leq 0.05.

Cell Type Signatures. Gene lists identifying cell-types within the brain and microglial and astrocytic sub-type were obtained from previously published studies (Chen et al., 2020, Friedman et al., 2018, Hammond et al., 2019, Keren-Shaul et al., 2017, Krasemann et al., 2017, Sala Frigerio et al., 2019, Zhang et al., 2014). Using these gene lists, the geometric mean of the FPKM (fragments per kilobase of exon per million mapped fragments) for genes identified for each cell or cellular sub-type was calculated on a per-animal basis. Group means were calculated, and between group significance values determined by one-way ANOVA. Outliers were removed from the group if their value fell outside of 1.5 times the inter-quartile range (IQR).

WGCNA. The WGCNA package in R (Langfelder & Horvath, 2008, Langfelder & Horvath, 2012) was used to construct gene correlation networks from the expression data after filtering and removing genes with zero variance. Soft power settings were chosen using the

"pickSoftThreshold" function within the WGCNA package. Networks were constructed separately for *APP* transgenic and non-transgenic samples. Adjacency matrices were constructed using expression data and these power setting with the "adjacency" function and a signed hybrid network. Module identification was performed using the "cutreeDynamic" function and a deepSplit setting of 2 with a minimum module size of 30 for all analyses. Modules with similar gene expression profiles were merged using the mergeModules function.

Functional annotation of DEGs, heatmap clusters and WGCNA modules. Gene ontology enrichment analysis was performed with goseq v1.42.0 (Young et al., 2010) to identify gene ontology categories and KEGG pathways that are affected for the given gene lists. For DEGs, up- and down-regulated gene lists were analyzed separately. For WGCNA, gene lists from each module were used as input and GOseq analysis was performed for each module separately. Overrepresented p-values were adjusted for multiple comparisons using the Benjamini-Hochberg adjustments for controlling false-discovery rates. An enrichment score was calculated by an observed-over-expected ratio of

(DEG/totalDEG)/(CategoryTotal/GeneTotal)

Where DEG represents the total number of DEGs or module genes within the GO or KEGG category, totalDEG represents the total number of DEGs or module genes; CategoryTotal represents the total number of genes within the GO or KEGG category and GeneTotal represents the total number of genes examined. GO terms and KEGG pathways are filtered for p-values adjusted for multiple comparisons (BHadjust) < 0.05, enrichment scores > 1 and total number of genes within the category > 5.

Gene lists to annotate WGCNA modules and identify microglia subtype signatures were identified from previously published studies (Chen et al., 2020, Dejanovic, Huntley et al., 2018,

Hammond et al., 2019, Keren-Shaul et al., 2017, Krasemann et al., 2017, Sala Frigerio et al., 2019, Zhang et al., 2014). Gene overlap analysis was conducted with the GeneOverlap package in R (<u>http://shenlab-sinai.github.io/shenlab-sinai/</u>). GeneOverlap uses Fisher's exact test to calculate the p-value for significance testing as well as calculating the odds ratio. goseq was used for GO and KEGG pathway analysis of genes within each module filtering for those terms with p-values < 0.05, enrichment scores > 1 and total number of genes within the category > 5.

Correlation analysis from human brains and mouse brains. To assess GNGT2 and ABI3 for correlation in human brain, RNAseq expression measures collected from two datasets representing three brain regions (TCX = temporal cortex, CER = cerebellum, DLPFC = dorsolateral prefrontal cortex) were obtained from the AD-knowledge portal (Mayo RNAseq and ROSMAP studies). The AMP-AD consortium previously reprocessed the raw format RNASeq data from these two studies through a consensus alignment, counting and quality control pipeline (RNAseq Harmonization Study). The reprocessed gene counts and associated metadata were downloaded and underwent further quality control, followed by CQN normalization of the raw counts for the 631 ROSMAP, 259 Mayo RNAseq TCX and 246 Mayo RNAseq CER samples that remained. For ROSMAP, four samples were excluded due to missing metadata, one sample removed due to inconsistent sex between provided metadata and expression of Y chromosome genes, and three samples removed based on being outliers (>4SD from mean, PC1 or PC2) in principal components analysis of the reprocessed gene counts (counts per million). For Mayo RNAseq, samples were excluded from the RNASeq datasets based on quality control (QC) outcomes provided in the metadata files. An additional 3 samples were removed due to being gene expression outliers following principal components analysis (>4SD from mean, PC1 or PC2) of the reprocessed gene counts (counts per million). CON normalized gene counts for ABI3 and *GNTG2* were extracted for each dataset and plotted in R-3.6.0 using ggplot2. The correlation in the expression between the two genes was assessed using the cor.test function (spearman) in R-3.6.0.

To examine the correlation between Gngt2 and Abi3 in the mouse cortex, bam sequencing alignment files from the TgCRND8 and rTg4510 mouse models were downloaded from the Tau and APP mouse model study at Synapse (10.7303/syn3157182). The gene counting step was performed with the summarizeOverlaps functions in the GenomicAlignments package (Lawrence et al., 2013) and counts were subsequently converted to FPKM with the DESeq2 package (Love et al., 2014) in R 4.1.0. Gngt2 and Abi3 FPKM values were extracted and plotted in R using the ggscatter function and spearman correlation method in the ggpubr package (https://CRAN.R-project.org/package=ggpubr).

In situ hybridization (RNAscope®, Advanced Cell Diagnostics, Newark, CA) and combined in situ hybridization/immunohistochemistry. For in-situ hybridization, 5µm thick paraffinembedded tissue sections on slides were rehydrated in xylene and series of ethanol solutions (100%, 90%, and 70%). Slides were incubated with RNAscope® Hydrogen peroxide for 10 min at RT, followed by antigen retrieval in steam for 15 min using RNAscope® 1x target retrieval reagent. After incubation in 10% ethanol for 3 min slides were air dried at 60°C. Subsequently, slides were incubated with RNAscope® Protease plus reagent for 30 min at 40°C in a HybEZTM oven, followed by 3 washes in distilled water. Slides were then incubated with the following RNAscope® probes (Mouse Abi3 (Cat No. 539161), human ABI3-O1 (Cat No. 549711)) for 2 hours at 40°C in a HybEZTM oven. Following washes with 1X Wash buffer, slides were incubated with RNAscope®AMP1 solution for 30 min at 40°C followed by series of washes in AMP buffers and incubation in RNAscope® Fast RED-B and RED-A mixture (1:60 ratio) for 10

min at RT. For immunohistochemistry double labeling, sections were incubated in Impress® horse serum (2.5%, Vector Laboratories) solution for 20 min, followed by a 5 min incubation in 2% FBS/0.1 M Tris, pH 7.6. Primary antibodies were diluted in 2% FBS/0.1 M Tris, pH 7.6 at the following dilutions: Iba1 (Wako), 1:500. Sections were incubated with primary antibody over night at 4°C, washed two times in 0.1 M Tris, pH 7.6 for 5 min each and incubated in ImmPress® anti-rabbit IgG plus reagent (Vector Laboratories) for 30 min at RT. After two washes in 0.1 M Tris, pH 7.6 for 5 min each, immunocomplexes were visualized using the chromogen 3,3′-diaminobenzidine (DAB kit; KPL, Gaithersburg, MD). Tissue sections were counterstained with hematoxylin (Sigma Aldrich, St. Louis, MO), air dried at 60°C for 15 min and cover slipped using EcoMount[™] mounting medium (Biocare Medical).

In vitro overexpression and phosphorylation analysis of ABI3. Plasmid encoding for ABI3 (NM_016428) was purchased from OriGene (Catalog# RC202853). Site directed mutagenesis in ABI3 was performed and resulting clones were Sanger sequenced to confirm the presence of mutation. HEK293T cells were grown in DMEM media supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Life Technologies) and transiently transfected by CaCl₂ method. 48 hours later, the transfected cells were lysed in RIPA buffer (Fisher) supplemented with complete EDTA-free Protease Inhibitor Cocktail and phosphatase inhibitor tablets (Sigma-Aldrich). Protein extracts were loaded on Bis-Tris precast gels (BioRad) were transferred on PVDF membrane for Western blotting with the Li-Cor system. ABI3 was detected with the following antibodies according to the experiment: FLAG-M2 (Sigma-Aldrich), N terminal Anti-ABI3 (Sigma-Aldrich) or anti-ABI3 209F (manufactured by Pacific Immunology Corp using the peptide sequence 195-PVVPDGRLSAASSAF-209). Lambda Protein Phosphatase (NEB) assay was performed as described by the supplier. Briefly, ABI3 HEK

transfected cells were lysed in PBS 0.1% NP-40 in the presence of complete protease inhibitor. Cytoplasmic proteins fractions were used for the reaction and analyzed by Western Blotting.

Statistical Analysis. Detailed description of statistics is provided in each figure legend and in the methods section. Statistical analysis was done using GraphPad Prism.

Acknowledgments. We thank the State of Florida Ed & Ethel Moore Alzheimer's Disease Research Program (8AZ16), NIH/NIA (U01 AG046139), University of Florida Neuromedicine Human Brain and Tissue Bank (funded in part by NIA P30AG066506) and McKnight Brain Institute for support. We posthumously thank Dr. Peter Davies for anti tau antibodies.

Author Contributions. PC conceived the study and wrote the manuscript; KRI performed immunohistochemistry, ELISA and western blots and assembled final figures; KNM extracted RNA, performed RNAseq and analyzed data; JL, TEG and SP performed in situ hybridization; MA, XW, ZQ, CF, TEG and NET performed informatics analysis on human AMP-AD data; CL performed in vitro experiments; LZ, SS and QV performed immunostaining and data analysis; EGDLC euthanized animals; PC maintained mouse colonies and performed neonatal injections; TEG and DR provided recombinant AAV. All authors read and reviewed the manuscript.

Conflict of Interests. The authors declare no competing interests.

Data and Code Availability. The full datasets and R codes supporting the current study are available from the corresponding author on request. On publication, these data will be deposited in AD Knowledge Portal (https://adknowledgeportal.org). The AD Knowledge Portal is a platform for accessing data, analyses, and tools generated by the Accelerating Medicines Partnership (AMP-AD) Target Discovery Program and other National Institute on Aging (NIA)-supported programs to enable open-science practices and accelerate translational learning. The

data, analyses and tools are shared early in the research cycle without a publication embargo on secondary use. Data is available for general research use according to the following requirements for data access and data attribution (<u>https://adknowledgeportal.org/</u>DataAccess/Instructions).

References

Al-Ouran R, Wan YW, Mangleburg CG, Lee TV, Allison K, Shulman JM, Liu Z (2019) A Portal to Visualize Transcriptome Profiles in Mouse Models of Neurological Disorders. Genes (Basel) 10: 759

Audrain M, Haure-Mirande JV, Wang M, Kim SH, Fanutza T, Chakrabarty P, Fraser P, St George-Hyslop PH, Golde TE, Blitzer RD, Schadt EE, Zhang B, Ehrlich ME, Gandy S (2019) Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry 24: 1383-1397 Bae J, Sung BH, Cho IH, Kim SM, Song WK (2012a) NESH regulates dendritic spine morphology and synapse formation. PloS one 7: e34677 Bae J, Sung BH, Cho IH, Song WK (2012b) F-actin-dependent regulation of NESH dynamics in rat hippocampal neurons. PloS one 7: e34514 Bagnat M, Keranen S, Shevchenko A, Simons K (2000) Lipid rafts function in biosynthetic delivery of proteins to the cell surface in yeast. Proc Natl Acad Sci USA 97: 3254-9 Beckman D, Chakrabarty P, Ott S, Dao A, Zhou E, Janssen WG, Donis-Cox K, Muller S, Kordower JH, Morrison JH (2021) A novel tau-based rhesus monkey model of Alzheimer's pathogenesis. Alzheimers Dement 6: 933-945 Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, Kokiko-Cochran ON, Crish SD, Lasagna-Reeves CA, Ransohoff RM, Landreth GE, Lamb BT (2017) TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener 12: 74 Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT (2010)

Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb B1 (2010) Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68: 19-31 Burberry A, Wells MF, Limone F, Couto A, Smith KS, Keaney J, Gillet G, van Gastel N, Wang JY, Pietilainen O, Qian M, Eggan P, Cantrell C, Mok J, Kadiu I, Scadden DT, Eggan K (2020)

C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature 582: 89-94

Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, Das P (2010) IFNgamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol 184: 5333-43

Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, Zubair AC, Dickson D, Golde TE, Das P (2010a) Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J 24: 548-59

Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, Sacino A, Nix S, Janus C, Price ND, Das P, Golde TE (2015) IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85: 519-33

Chakrabarty P, Rosario A, Cruz P, Siemienski Z, Ceballos-Diaz C, Crosby K, Jansen K, Borchelt DR, Kim JY, Jankowsky JL, Golde TE, Levites Y (2013) Capsid Serotype and Timing of Injection Determines AAV Transduction in the Neonatal Mice Brain. PloS one 8: e67680 Chen WT, Lu A, Craessaerts K, Pavie B, Sala Frigerio C, Corthout N, Qian X, Lalakova J, Kuhnemund M, Voytyuk I, Wolfs L, Mancuso R, Salta E, Balusu S, Snellinx A, Munck S, Jurek A, Fernandez Navarro J, Saido TC, Huitinga I et al. (2020) Spatial Transcriptomics and In Situ

Sequencing to Study Alzheimer's Disease. Cell 182: 976-991 e19

Conway OJ, Carrasquillo MM, Wang X, Bredenberg JM, Reddy JS, Strickland SL, Younkin CS, Burgess JD, Allen M, Lincoln SJ, Nguyen T, Malphrus KG, Soto AI, Walton RL, Boeve BF, Petersen RC, Lucas JA, Ferman TJ, Cheshire WP, van Gerpen JA et al. (2018) ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Mol Neurodegener 13: 53

Courtney KD, Grove M, Vandongen H, Vandongen A, LaMantia AS, Pendergast AM (2000) Localization and phosphorylation of Abl-interactor proteins, Abi-1 and Abi-2, in the developing nervous system. Mol Cell Neurosci 16: 244-57

Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC,

Fagan AM, Holtzman DM (2010) YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68: 903-12

Dani M, Wood M, Mizoguchi R, Fan Z, Walker Z, Morgan R, Hinz R, Biju M, Kuruvilla T,

Brooks DJ, Edison P (2018) Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. Brain 141: 2740-2754

Dansokho C, Heneka MT (2018) Neuroinflammatory responses in Alzheimer's disease. J Neural Transm (Vienna) 125: 771-779

Dejanovic B, Huntley MA, De Maziere A, Meilandt WJ, Wu T, Srinivasan K, Jiang Z, Gandham V, Friedman BA, Ngu H, Foreman O, Carano RAD, Chih B, Klumperman J, Bakalarski C,

Hanson JE, Sheng M (2018) Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies. Neuron 100: 1322-1336 e7

Deming Y, Filipello F, Cignarella F, Cantoni C, Hsu S, Mikesell R, Li Z, Del-Aguila JL, Dube

U, Farias FG, Bradley J, Budde J, Ibanez L, Fernandez MV, Blennow K, Zetterberg H,

Heslegrave A, Johansson PM, Svensson J, Nellgard B et al. (2019) The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. Sci Transl Med 11: eaau2291

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras

TR (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29: 15-21

Efthymiou AG, Goate AM (2017) Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk. Mol Neurodegener 12: 43

Erny D, Hrabe de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, Keren-Shaul H,

Mahlakoiv T, Jakobshagen K, Buch T, Schwierzeck V, Utermohlen O, Chun E, Garrett WS,

McCoy KD, Diefenbach A, Staeheli P, Stecher B, Amit I, Prinz M (2015) Host microbiota

constantly control maturation and function of microglia in the CNS. Nat Neurosci 18: 965-77

Fan Z, Brooks DJ, Okello A, Edison P (2017) An early and late peak in microglial activation in Alzheimer's disease trajectory. Brain 140: 792-803

Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, Modrusan Z, Larson JL, Kaminker JS, van der Brug MP, Hansen DV (2018) Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer's Disease Not Evident in Mouse Models. Cell Rep 22: 832-847 Friker LL, Scheiblich H, Hochheiser IV, Brinkschulte R, Riedel D, Latz E, Geyer M, Heneka MT (2020) beta-Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia. Cell Rep 30: 3743-3754 e6

Ghosh S, Wu MD, Shaftel SS, Kyrkanides S, LaFerla FM, Olschowka JA, O'Banion MK (2013) Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci 33: 5053-64

Golde TE (2019) Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. Neuron 101: 1003-1015

Griciuc A, Patel S, Federico AN, Choi SH, Innes BJ, Oram MK, Cereghetti G, McGinty D, Anselmo A, Sadreyev RI, Hickman SE, El Khoury J, Colonna M, Tanzi RE (2019) TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease. Neuron 103: 820-835 e7

Hamelin L, Lagarde J, Dorothee G, Leroy C, Labit M, Comley RA, de Souza LC, Corne H, Dauphinot L, Bertoux M, Dubois B, Gervais P, Colliot O, Potier MC, Bottlaender M, Sarazin M, Clinical It (2016) Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. Brain 139: 1252-64

Hammond TR, Dufort C, Dissing-Olesen L, Giera S, Young A, Wysoker A, Walker AJ, Gergits F, Segel M, Nemesh J, Marsh SE, Saunders A, Macosko E, Ginhoux F, Chen J, Franklin RJM, Piao X, McCarroll SA, Stevens B (2019) Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. Immunity 50: 253-271 e6

Hansen DV, Hanson JE, Sheng M (2018) Microglia in Alzheimer's disease. J Cell Biol 217: 459-472

Haure-Mirande JV, Wang M, Audrain M, Fanutza T, Kim SH, Heja S, Readhead B, Dudley JT, Blitzer RD, Schadt EE, Zhang B, Gandy S, Ehrlich ME (2019) Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in cerebral Abeta amyloidosis mouse normalizes clinical phenotype and complement subnetwork molecular pathology without reducing Abeta burden. Mol Psychiatry 24: 431-446

Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT (2013) NLRP3 is

38

activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493: 674-8

Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nature Rev Neurosci 16: 358-72

Huang CH, Lin TY, Pan RL, Juang JL (2007) The involvement of Abl and PTP61F in the regulation of Abi protein localization and stability and lamella formation in Drosophila S2 cells. J Biol Chem 282: 32442-52

Ichigotani Y, Yokozaki S, Fukuda Y, Hamaguchi M, Matsuda S (2002) Forced expression of NESH suppresses motility and metastatic dissemination of malignant cells. Cancer Res 62: 2215-9

Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, Schwartz S, Albasset S, McManus RM, Tejera D, Griep A, Santarelli F, Brosseron F, Opitz S, Stunden J, Merten M, Kayed R, Golenbock DT, Blum D, Latz E et al. (2019) NLRP3 inflammasome activation drives tau pathology. Nature 575: 669-673

Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R et al. (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dementia 14: 535-562

Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HTJ, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982

Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT (2015) TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 212: 287-95

Karahan H, Smith DC, Kim B, Dabin LC, Al-Amin MM, Wijeratne HRS, Pennington T, Viana di Prisco G, McCord B, Lin PB, Li Y, Peng J, Oblak AL, Chu S, Atwood BK, Kim J (2021)

Deletion of Abi3 gene locus exacerbates neuropathological features of Alzheimer's disease in a mouse model of Abeta amyloidosis. Sci Adv 7: eabe3954

Karran E, De Strooper B (2016) The amyloid cascade hypothesis: are we poised for success or failure? J Neurochem 139 Suppl 2: 237-252

Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK,

David E, Baruch K, Lara-Astaiso D, Toth B, Itzkovitz S, Colonna M, Schwartz M, Amit I (2017) A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.

Cell 169: 1276-1290 e17

Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y) 4: 575-590

Koller EJ, Gonzalez De La Cruz, E., Machula, T., Ibanez, K.R., Lin, W-L., Williams, T., Riffe, C.J., Ryu, D., Strang, K.H., Liu, X., Janus, C., Golde, T.E., Dickson, D.W., Giasson, B.I., Chakrabarty, P. (2019) Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy. Hum Mol Genet 19: 3255-3269

Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin

E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, Conde-Sanroman P,

Gacias M, Weng Z, Chen H, Tjon E et al. (2017) The TREM2-APOE Pathway Drives the

Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47: 566-581 e9

Lananna BV, McKee CA, King MW, Del-Aguila JL, Dimitry JM, Farias FHG, Nadarajah CJ,

Xiong DD, Guo C, Cammack AJ, Elias JA, Zhang J, Cruchaga C, Musiek ES (2020)

Chi311/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis. Sci Transl Med 12

Langfelder P, Horvath S (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9: 559

Langfelder P, Horvath S (2012) Fast R Functions for Robust Correlations and Hierarchical Clustering. J Stat Softw 46

Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, Morgan MT, Carey VJ (2013) Software for computing and annotating genomic ranges. PLoS Comput Biol 9: e1003118

Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM, Lamb BT (2010) CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol 177: 2549-62

Lee SH, Meilandt WJ, Xie L, Gandham VD, Ngu H, Barck KH, Rezzonico MG, Imperio J,

Lalehzadeh G, Huntley MA, Stark KL, Foreman O, Carano RAD, Friedman BA, Sheng M,

Easton A, Bohlen CJ, Hansen DV (2021) Trem2 restrains the enhancement of tau accumulation and neurodegeneration by beta-amyloid pathology. Neuron 109: 1283-1301 e6

Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, Holtzman DM (2017) TREM2 deficiency attenuates

neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci USA 114: 11524-11529

Li A, Ceballos-Diaz C, DiNunno N, Levites Y, Cruz PE, Lewis J, Golde TE, Chakrabarty P (2015) IFN-gamma promotes tau phosphorylation without affecting mature tangles. FASEB J 29: 4384-98

Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B et al. (2017) Neurotoxic

reactive astrocytes are induced by activated microglia. Nature 541: 481-487

Liu CY, Yang Y, Ju WN, Wang X, Zhang HL (2018) Emerging Roles of Astrocytes in Neuro-Vascular Unit and the Tripartite Synapse With Emphasis on Reactive Gliosis in the Context of Alzheimer's Disease. Frontiers Cellular Neurosci 12: 193

Liu Y, Beyer A, Aebersold R (2016) On the Dependency of Cellular Protein Levels on mRNA Abundance. Cell 165: 535-50

Llorens F, Thune K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, Kovatsi E, Pleschka C, Garcia-Esparcia P, Schmitz M, Ozbay D, Correia S, Correia A, Milosevic I, Andreoletti O, Fernandez-Borges N, Vorberg IM, Glatzel M, Sklaviadis T, Torres JM et al. (2017) YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener 12: 83 Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15: 550

Magno L, Lessard CB, Martins M, Lang V, Cruz P, Asi Y, Katan M, Bilsland J, Lashley T, Chakrabarty P, Golde TE, Whiting PJ (2019) Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimer's Research Ther 11: 16 Meilandt WJ, Ngu H, Gogineni A, Lalehzadeh G, Lee SH, Srinivasan K, Imperio J, Wu T, Weber M, Kruse AJ, Stark KL, Chan P, Kwong M, Modrusan Z, Friedman BA, Elstrott J, Foreman O, Easton A, Sheng M, Hansen DV (2020) Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Abeta42:Abeta40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model. J Neurosci 40: 1956-1974

Mendoza MC (2013) Phosphoregulation of the WAVE regulatory complex and signal integration. Semin Cell Dev Biol 24: 272-9

Miyazaki K, Matsuda S, Ichigotani Y, Takenouchi Y, Hayashi K, Fukuda Y, Nimura Y, Hamaguchi M (2000) Isolation and characterization of a novel human gene (NESH) which encodes a putative signaling molecule similar to e3B1 protein. Biochimica et biophysica acta 1493: 237-41

Nisbet RM, Polanco JC, Ittner LM, Gotz J (2015) Tau aggregation and its interplay with amyloid-beta. Acta Neuropathol 129: 207-20

Ong OC, Hu K, Rong H, Lee RH, Fung BK (1997) Gene structure and chromosome localization of the G gamma c subunit of human cone G-protein (GNGT2). Genomics 44: 101-9 Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, Muller SA, Colombo A, Monasor LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O et al. (2019) Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci 22: 191-204

Patir A, Shih B, McColl BW, Freeman TC (2019) A core transcriptional signature of human microglia: Derivation and utility in describing region-dependent alterations associated with Alzheimer's disease. Glia 67: 1240-1253

Sala Frigerio C, Wolfs L, Fattorelli N, Thrupp N, Voytyuk I, Schmidt I, Mancuso R, Chen WT, Woodbury ME, Srivastava G, Moller T, Hudry E, Das S, Saido T, Karran E, Hyman B, Perry VH, Fiers M, De Strooper B (2019) The Major Risk Factors for Alzheimer's Disease: Age, Sex, and Genes Modulate the Microglia Response to Abeta Plaques. Cell Rep 27: 1293-1306 e6

42

Satoh JI, Kino Y, Yanaizu M, Tosaki Y, Sakai K, Ishida T, Saito Y (2017) Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease. Intractable Rare Dis Res 6: 262-268

Sayed FA, Telpoukhovskaia M, Kodama L, Li Y, Zhou Y, Le D, Hauduc A, Ludwig C, Gao F,

Clelland C, Zhan L, Cooper YA, Davalos D, Akassoglou K, Coppola G, Gan L (2018)

Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy. Proc Natl Acad Sci USA 115: 10172-10177

Sekino S, Kashiwagi Y, Kanazawa H, Takada K, Baba T, Sato S, Inoue H, Kojima M, Tani K (2015) The NESH/Abi-3-based WAVE2 complex is functionally distinct from the Abi-1-based WAVE2 complex. Cell Commun Signal 13: 41

Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK (2007)

Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117: 1595-604

Shi Y, Holtzman DM (2018) Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nature Reviews Immunol 18: 759-772

Siddiqui TA, Lively S, Vincent C, Schlichter LC (2012) Regulation of podosome formation, microglial migration and invasion by Ca(2+)-signaling molecules expressed in podosomes. J Neuroinflamm 9: 250

Simonazzi E, Jones RE, Chen F, Ranson A et al (2021) Abi3 regulates microglial ramification and dynamic tissue surveillance in vivo. bioRxiv 10.1101/2021.03.19.436147

Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW,

Boland A, Raybould R, Bis JC, Martin ER, Grenier-Boley B, Heilmann-Heimbach S, Chouraki

V, Kuzma AB, Sleegers K, Vronskaya M, Ruiz A, Graham RR, Olaso R et al. (2017) Rare

coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature genetics 9: 1373-1384

Walker DG (2020) Defining activation states of microglia in human brain tissue: an unresolved issue for Alzheimer's disease. Neuroimmunol Neuroinflammation 7: 194-214

Wan YW, Al-Ouran R, Mangleburg CG, Perumal TM, Lee TV, Allison K, Swarup V, Funk CC, Gaiteri C, Allen M, Wang M, Neuner SM, Kaczorowski CC, Philip VM, Howell GR, Martini-Stoica H, Zheng H, Mei H, Zhong X, Kim JW et al. (2020) Meta-Analysis of the Alzheimer's

Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. Cell Rep 32: 107908

Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, Rongve A, Borte S, Winsvold BS, Drange OK, Martinsen AE, Skogholt AH, Willer C, Brathen G, Bosnes I, Nielsen JB, Fritsche LG, Thomas LF, Pedersen LM, Gabrielsen ME et al. (2021) A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet 53: 1276-1282

Yao Z, van Velthoven CTJ, Nguyen TN, Goldy J, Sedeno-Cortes AE, Baftizadeh F, Bertagnolli D, Casper T, Chiang M, Crichton K, Ding SL, Fong O, Garren E, Glandon A, Gouwens NW, Gray J, Graybuck LT, Hawrylycz MJ, Hirschstein D, Kroll M et al. (2021) A taxonomy of transcriptomic cell types across the isocortex and hippocampal formation. Cell 184: 3222-3241 e26

Young MD, Wakefield MJ, Smyth GK, Oshlack A (2010) Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol 11: R14

Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, Fluder E, Clurman B, Melquist S, Narayanan M, Suver C, Shah H, Mahajan M, Gillis T, Mysore J, MacDonald ME et al. (2013) Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 153: 707-20

Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Barres BA, Wu JQ (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34: 11929-47

Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, Cella M, Ulland TK, Zaitsev K, Miyashita A, Ikeuchi T, Sainouchi M, Kakita A, Bennett DA, Schneider JA, Nichols MR et al. (2020) Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nat Med 26: 131-142

Figure Legends

Fig. 1. ABI3 RNA is expressed in microglia and neurons in mice and humans. a-b. Abi3 RNA levels (FKPM) plotted across different ages in *APP* CRND8 mice (a) and *MAPT* rTg4510 mice (b). Data obtained from AMP-AD Synapse data from UF-Mayo group. n=9-14 (a) and n=6 (b). 1 way Anova, ****p<0.0001; **p<0.01; *p<0.05. c-j. In situ hybridization was done to detect ABI3 (Fast Red; red color) RNA on human and mouse paraffin embedded brain sections immunostained with anti Iba-1 antibody (brown color). Asterisks mark Aβ deposits; arrowheads indicate Iba-1 (microglia) associated in situ signal and arrows indicate in situ signal in nonmicroglia cells. n=3 (human AD cases, 6 month old TG-*Abi3-Gngt2*^{-/-} mice and 6 month old TG-*Abi3-Gngt2*^{+/+} mice) and n=1 (20 month old TgCRND8 mice). Representative of two independent experimental replicates. Additional representative images are available in Fig. EV1. NonTG, nontransgenic; TG, transgenic.

Fig. 2. ABI3 and GNGT2 genes are in a co-regulatory expression network.

a-c. Graphs showing co-regulation of ABI3 and GNGT2 RNA counts from Mayo cohorts (temporal cortex, TCX and Cerebellum, CER) and ROSMAP cohort. Data derived from AMP-AD synapse. d-e. Graphs showing co-regulation of ABI3 and GNGT2 RNA counts from *APP* TgCRND8 and *MAPT* rTg4510 mice. ρ indicates correlation coefficient and p values are adjusted for multiple analysis. Data derived from AMP-AD synapse. f. Table depicting the correlation coefficient (ρ) and p values for each cohort depicted in a-e.

Fig. 3. Immune activation in Abi3-Gngt2 deficient mice.

Representative images of Iba-1 reactive microglia (a-f) and GFAP reactive astrocyte (g-l) in 3 month old or 6 month old mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of *Abi3-Gngt2* genes. Quantitation of the Iba-1 or GFAP staining from cortex or hippocampus is

provided in corresponding panels on the right side. N=6 mice (a-f), 7 mice (g-l). Scale bar, 50µm. Clear symbols indicate female mice and filled symbols represent male mice. n=4 females, 2 males. Data represents mean±sem. 1 way Anova; ***p<0.001; **p<0.01; *p<0.05.

Fig. 4. Unbiased transcriptomic analysis of *Abi3-Gngt2* deficient mice reveal upregulation of immune pathways and disease-related gene expression patterns.

a-c. Volcano plot (a), list of top 5 upregulated and top 5 downregulated genes (based on fold change) (b) and GO pathways based on enriched genes (c) in 3 month old Abi3-Gngt2^{-/-} mice relative to *Abi3-Gngt2*^{+/+} mice. Orange dots, upregulated genes; blue dots, downregulated genes. FC= fold change. d-g. Gene expression signatures of microglia (d), astrocytes (e), neurons (f) and oligodendrocytes (g) in 3 month old mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of Abi3-Gngt2 locus. h-m. Gene expression signatures for specific microglia (h-k) or astrocyte (l, m) subtypes in 3 month old mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of *Abi3-Gngt2* locus. These cell-type specific signatures were identified in previous studies (Chen et al., 2020, Keren-Shaul et al., 2017, Krasemann et al., 2017, Liddelow et al., 2017, Sala Frigerio et al., 2019). n-o. WGCNA gene co-expression modules correlating with specific experimental traits (inflammation burden and *Abi3-Gngt2^{-/-}* genotype) shown (n). Correlation of modules to different experimental traits are colored in a heatmap (red, positive correlation; blue, negative correlation). Modules with p-values < 0.05 and an absolute correlation value < 0.5 are indicated in grey. Cell-type specific gene lists were used to identify genes with significant overlap (odds ratio) within the modules. The heatmap is colored by the value of the odds ratio. Grey squares indicate non-significant (p<0.05, odds ratio < 2) overlaps in the gene lists. o. Genes within WGCNA modules enriched for known KEGG pathways based on over-representation of enriched genes is depicted in a bubble plot (o). Pathways with an over-represented p-value \leq 0.05, the number of module genes within the pathway >5 and an enrichment score >1.5 are depicted. The bubble plot is colored by p-value and sized by the enrichment score. All p values adjusted for multiple comparisons (padj). n=4 mice (2 males, 2 females) per *Abi3-Gngt2* genotype except 1 outlier removed in d-m. 1 way Anova (D-M), **p<0.01, *p<0.05.

Fig. 5. Loss of Abi3-Gngt2 expression ameliorates Aβ in a gene-dosage manner.

a-b. Representative immunohistochemical images of A β plaques and quantification in 3 month old APP TG mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of Abi3-Gngt2 locus. c-d. Representative images of thioflavin S-stained A β plaques and quantitation in 3 month old APP TG mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of Abi3-Gngt2 locus. e-h. Biochemical levels of formic acid (FA) solubilized and detergent (SDS) soluble Aβ42 and Aβ40 in 3 month old APP TG mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of Abi3-Gngt2 locus, i-j. Representative immunohistochemical images of A β plaques and quantification in 6 month old APP transgenic mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of Abi3-Gngt2 locus. k-l. Representative images of thioflavin S-stained plaques and quantitation in 6 month old APP TG mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of Abi3-Gngt2 locus. m-p. Biochemical levels of FA solubilized and SDS soluble A\u00e542 and A\u00e540 in 6 month old APP TG mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of Abi3-Gngt2 locus. N=6 mice (a-h), 7 mice (i-p). Scale bar, 50µm (a, k); 100µm (c, m). Clear symbols indicate female mice and filled symbols represent male mice. n=3 females, 3 males (3 months) and n=3 females, 4 males (6 months). Data represents mean±sem. 1 way Anova; ***p<0.001; **p<0.01; *p<0.05.

Fig. 6. Abi3-Gngt2 regulates microgliosis and astrocytosis in APP mice.

Representative images of Iba-1 reactive microglia (a-f) and GFAP reactive astrocyte (g-l) in 3 month old or 6 month old *APP* transgenic mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of *Abi3* locus. Quantitation of the Iba-1 or GFAP staining from cortex or hippocampus is provided in corresponding panels on the right side. Scale bar, 50µm. Clear symbols indicate female mice and filled symbols represent male mice. n=3 females, 3 males (3 months) and n=3 females, 4 males (6 months). Data represents mean±sem. 1 way Anova; ***p<0.001; **p<0.01; **p<0.05.

Fig. 7. Unbiased transcriptomic analysis of TG-*Abi3-Gngt2^{-/-}* mice reveal distinctive disease-associated gene expression signatures and co-expression modules.

a-c. Volcano plot (a), list of top 5 upregulated and top 5 downregulated genes (based on fold change) (b) and GO pathways based on enriched genes for upregulated genes (c) in 3 month old *APP* TG mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of *Abi3-Gngt2* locus. Orange dots, upregulated genes; blue dots, downregulated genes. FC=fold change. d-g. Gene expression signatures of microglia (d), astrocytes (e), neurons (f) and oligodendrocytes (g) in 3 month old *APP* TG mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of *Abi3-Gngt2* locus. h-m. Gene expression signatures for specific microglia (h-k) or astrocyte (l, m) subtypes in 3 month old *APP* TG mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of *Abi3-Gngt2* locus. h-m. Gene expression signatures for specific microglia (h-k) or astrocyte (l, m) subtypes in 3 month old *APP* TG mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of *Abi3-Gngt2* locus. n-o. WGCNA gene co-expression modules correlating with experimental traits (Aβ values, inflammation burden) with *Abi3-Gngt2* genotype shown (n). Correlation of modules to different experimental traits are colored in a heatmap (red, positive correlation; blue, negative correlation). Modules with p-values<0.05 and an absolute correlation value < 0.5 are indicated in grey. Cell-type specific gene lists were used to identify genes with significant overlap (odds ratio) within the modules. The heatmap is colored by the value of the odds ratio. Grey squares

indicate non-significant (p<0.05, odds ratio < 2) overlaps in the gene lists. o. Genes within WGCNA modules enriched for known KEGG pathways depicted in a bubble plot. Pathways with an over-represented p-value ≤ 0.05 , the number of module genes within the pathway >5 and an enrichment score >1.5 are depicted. The bubble plot is colored by p-value and sized by the enrichment score. N=4 mice (2 males, 2 females) per *Abi3-Gngt2* genotype except 1 outlier removed in d-m. All p values adjusted for multiple comparisons (padj). 1 way Anova (D-M); **p<0.01, *p<0.05.

Fig. 8. Abi3-Gngt2 deficiency accelerates tauopathy in a mutant human tau model.

Mice were injected with control vector (Control) or AAV expressing a double mutant (P301L/S320F) human tau on neonatal day P0 and analyzed at 3 months (a-f) or 6 months (g-l). Representative brain images of total human tau (detected with CP27 antibody, a, g), ptau (detected with CP13 antibody, c, i) and misfolded pretangle tau (detected with MC1 antibody, e, k) from cortex and hippocampus of wild type BL/6 mice (+/+) and *Abi3-Gngt2^{-/-}* (-/-) mice are shown. Quantitative analysis of antibody-stained slides (b, d, f, h, j, l) shown on right side of corresponding stained brain images (a, c, e, g, i, k). Scale bar, 75 µm. n=6 mice/group. Data represents mean±sem. 1 way Anova; ****p<0.0001; ***p<0.001; **p<0.01; **p<0.05.

Fig. 9. Upregulation of astrocytosis in tau expressing *Abi3-Gngt2^{-/-}* mice.

Mice were injected with control vector (Control) or AAV expressing a double mutant (P301L/S320F) human tau on neonatal day P0 and analyzed at indicated time points. Representative images of Iba-1 reactive microglia (a-d) and GFAP reactive astrocyte (e-h) in 3 month old or 6 month old mice with intact (+/+) or complete loss (-/-) of *Abi3-Gngt2* locus. Quantitation of the Iba-1 or GFAP staining is provided in corresponding panels on the right side.

N=6 mice/group. Scale bar, 75 μm. Data represents mean±sem. 1 way Anova; ****p<0.0001; ***p<0.001; ***p<0.001; ***p<0.01; ***p<0.05.

Fig. 10. S209F mutation leads to altered phosphorylation in ABI3 protein.

a. HEK293T cells were transiently transfected with WT ABI3 or S209F ABI3 and separated on an immunoblot showing two distinct bands around 50kDa. Higher bands that are as yet uncharacterized (marked by asterisk) are also denoted. The proteins were detected with two antibodies simultaneously using LiCor infrared dyes: anti FLAG antibody (green) and anti S209-ABI3 antibody (red). b. Lambda protein phosphatase assay performed at 30°C on WT ABI3 and S209F ABI3 protein detected with anti FLAG antibody. c-d. HEK293T cells were transiently transfected with WT ABI3 or ABI3 mutated at position 209 and separated on an immunoblot. The proteins were detected with two antibodies simultaneously using LiCor infrared dyes: anti FLAG antibody (green) and anti S209-ABI3 antibody (red) or anti N terminal ABI3 (Sigma) (red). 'Mock' denotes sham transfection procedure with no DNA used in transfection. Asterisk marks an ABI3 derived band that has not been characterized. Data representative of at least two independent experimental replicates.

Fig. 11. Schematic depiction of Abi3-Gngt2 function. Our experiments with *Abi3-Gngt2* deficient model show that immune phenotype in these mice reduce $A\beta$ plaques in a gene-dose and age-dependent manner but increase tau phosphorylation early on (a). Loss of Abi3-Gngt2 function leads to early-life induction of AD/amyloid-associated factors and microglial genetic risk factors, independent of A β . In fact, these same microglial factors (as tabulated in a) are upregulated as humans progress from healthy status to AD (b). Based on our data, we hypothesize that a normally functioning Abi3 would lead to suppression of immunity (by suppressing induction of AD disease microglial risk factor genes), thus increasing A β plaques

but preventing tau phosphorylation and tangle formation (c). The neuropathology in the *Abi3-Gngt2* deficient model is reminiscent of the dichotomy observed in multiple mouse models testing microglial AD risk factors. The differential response of A β and tau to immune activation necessitates a cautious foray into immune-targeted therapies. Our in vitro data shows that the AD associated S209F mutation dramatically reduces self-phosphorylation, which guided by previous data from ABI family of proteins, would imply a loss of function phenotype (d). Brain picture adapted from online (CC license, b).

Expanded View (Supplementary) Figure Legends

Fig. EV1. Localization and levels of ABI3 RNA in human and mouse.

In situ hybridization was done to detect Abi3 RNA on human (a-f) and mouse (g-x) paraffin embedded brain sections. Human or mouse ABI3 specific RNAscope probes were used for in situ hybridization detected by Fast Red (red color) followed by immunohistochemistry for Iba-1 antibody detected by DAB (brown color). Three representative forebrain images in the vicinity or away from amyloid plaques are shown. Asterisks mark $A\beta$ deposits; arrowheads indicate Iba-1 (microglia) associated in situ signal and arrows indicate in situ signal in non-microglia cells. n=3 (human AD cases, 6 month old TG-*Abi3-Gngt2^{-/-}* mice and 6 month old TG-*Abi3-Gngt2^{+/+}* mice mice) and n=1 (20 month old TgCRND8 mice, collected independent of this study). Representative of two independent experimental replicates. TG= transgenic CRND8. Also see Fig. 1.

Fig. EV2. Genomic organization at the Abi3 locus of Mus musculus.

a. RNAseq based confirmation of Abi3, Gngt2 and APP levels from three *Abi3* genotypes (WT +/+, heterozygous +/-, homozygous -/-) in *APP* transgenic mice or NonTG (*APP* nTG)

littermates. b. The *Abi3* knock-out mice (Abi3tm1.1(KOMP)Vlcg) was generated by cremediated excision of the parental Abi3tm1(KOMP)Vlcg allele resulting in the removal of the neomycin selection cassette, leaving behind the inserted lacZ reporter sequence. The sequence that was excised out on chromosome 11 was located between 95842143 and 95832627.

Fig. EV3. Hub genes characteristic of WGCNA modules identified in 3 month old *Abi3-Gngt2^{-/-}* mice.

a. Volcano plot and table of altered genes representing DEG in 3 month old Abi3-Gngt2^{+/-} vs Abi3-Gngt2^{+/+} mice. FC, fold change; padj, adjusted p value. b-g. Module membership is plotted against gene connectivity (kWithin) for genes identified within modules significantly correlated with *Abi3-Gngt2* genotype and other neuropathology traits in TG-*Abi3-Gngt2^{-/-}* mice. The top 10 hub genes (as ranked by kWithin values) identified in each co-expression WGCNA modules of 3 month old Abi3-Gngt2^{-/-} mice relative to Abi3-Gngt2^{+/+} mice. The module members of antiquewhite2, coral2 and mediumpurple2 modules are shown (b, d, f), with top hub genes tabulated (c, e, g). Module statistics are denoted by: kWithin, extent of gene connectivity within the module; MM, module membership value (of gene to module); GS, gene significance value to specific experimental trait. H. The overlap of genes within WGCNA modules with genes previously identified in microglial and astrocytic sub-types is expressed as odds ratio value. The different cell signatures are: neurotoxic A1 and neurotrophic A2 astrocyte (Liddelow et al., 2017); PIG network (Chen et al., 2020); DAM (Keren-Shaul et al., 2017); MGnD and homeostatic microglia (Krasemann et al., 2017). Higher odds ratio denotes higher correlation. All p values are adjusted for multiple testing. Grey boxes indicate non-significant odds ratio values (p-value < 0.5). N=4 mice (2 male, 2 female) per cohort.

Fig. EV4. Neuropathological attributes of TG-Abi3-Gngt2^{-/-} mice.

a-b. Anti CT20 immunoblot indicating full length APP and C terminal fragments (CTF) in *APP* transgenic mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of *Abi3-Gngt2* (a). Lane marked with asterisk denotes a non transgenic mice for *APP* (a). APP levels normalized to actin is depicted (b). Ubiquitin decorating A β plaques in 3 month (c) and 6 month old (d) *APP* TG mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of *Abi3-Gngt2*. Scale Bar, 2mm (whole brain), 50 µm (cortex and hippocampus). e-m. Representative brain images stained with 33.1.1 antibody and corresponding quantitation (e-f), GFAP antibody and corresponding quantitation (g-h), Iba-1 antibody and corresponding quantitation (i-j), cd11b and corresponding quantitation (k-1) and ubiquitin decorated A β plaques (m) in 9 month old *APP* TG mice with intact (+/+), or partial loss (+/-) of *Abi3-Gngt2*. Scale Bar, 2 mm (whole brain), 50 µm (cortex and hippocampta). N=7-8 mice/genotype. Data represents mean±sem.

Fig. EV5. Synaptic protein levels in TG-*Abi3-Gngt2^{-/-}* mice.

Immunoblotting depicting levels of synaptic proteins in 3 month old *APP* TG mice with intact (+/+), partial loss (+/-) or complete loss (-/-) of *Abi3-Gngt2* (a, c, e, g, i, k, m). Quantitation of the synaptic proteins normalized to actin or GAPDH is depicted (b, d, f, h, j, l, n). Molecular weight markers in kDa are indicated on each panel. Data represents mean±sem. 1 way Anova; **p<0.01; *p<0.05.

Fig. EV6. Hub genes characteristic of WGCNA modules identified in 3 month old TG-*Abi3-Gngt2^{-/-}* mice.

a. No significant genes were identified in 3 month old TG-*Abi3-Gngt2*^{+/-} mice relative to TG-*Abi3-Gngt2*^{-/-} mice. FC, fold change; padj, adjusted p value. b-g. Module membership is plotted against gene connectivity (kWithin) for genes identified within modules significantly correlated

with *Abi3-Gngt2* genotype and other neuropathology traits in TG-*Abi3-Gngt2^{-/-}* mice. The top 10 hub genes (as ranked by kWithin values) identified in each co-expression WGCNA modules of 3 month old TG-*Abi3-Gngt2^{-/-}* mice relative to TG-*Abi3-Gngt2^{+/+}* mice. The module members of honeydew1, plum3 and sienna3 modules are shown (b, d, f), with top hub genes tabulated (c, e, g). Module statistics are denoted by: kWithin, extent of gene connectivity within the module; MM, module membership value (of gene to module); GS, gene significance value to specific experimental trait. h. The overlap of genes within WGCNA modules with genes previously identified in microglial and astrocytic sub-types signatures is expressed as odds ratio value. The different cell signatures are: neurotoxic A1 and neurotrophic A2 astrocyte (Liddelow et al., 2017); Plaque-induced gene (PIG) network (Bagnat, Keranen et al., 2000); Disease-associated microglia (DAM) (Keren-Shaul et al., 2017); microglial neurodegenerative phenotype (MGnD) and homeostatic microglia (Krasemann et al., 2017). All p values are adjusted for multiple testing (padj). Higher odds ratio denotes higher correlation. Grey boxes indicate non-significant odds ratio values (p-value < 0.5). 4 mice (2 male, 2 female) per cohort.

Fig. EV7. Somatic transgenesis modeling of tauopathy in *Abi3-Gngt2^{-/-}* mice.

a-c. Mice were injected with control vector (Control) or AAV expressing a double mutant (P301L/S320F) human tau on neonatal day P0 and analyzed at 3 months or 6 months. a. Representative images of ThioS-stained cortex of *Abi3-Gngt2*^{+/+} or *Abi3-Gngt2*^{-/-} mice injected with AAV-P301L/S320F tau or control vector shown. Three individual mice from each cohort are shown. b-c. Guanidine-insoluble brain lysates of AAV-P301L/S320F tau expressing *Abi3-Gngt2*^{+/+} or *Abi3-Gngt2*^{-/-} mice were separated on an immunoblot and probed with CP27 antibody (b) or CP13 antibody (c) to show presence of insoluble NFT tau. N=3 mice/condition. d-s. Mice were injected with control vector (Control) or AAV expressing wild type human tau on

neonatal day P0 and analyzed at 3 months or 6 months. Representative brain images of total human tau (detected with CP27 antibody, d, l), ptau (detected with CP13 antibody, f, n), astrocytes (detected with GFAP antibody, h, p) and microglia (detected with Iba-1 antibody, j, r) from cortex and hippocampus of *Abi3-Gngt2^{+/+}* or *Abi3-Gngt2^{-/-}* mice are shown. Quantitative analysis of antibody-stained brain sections (e, g, i, k, m, o, q, s) shown below corresponding stained brain images (d, f, h, j, l, n, p, r). Quantitative data in the graphs depicting the control vector cohort (*Abi3-Gngt2^{+/+}* or *Abi3-Gngt2^{-/-}* genotypes) is shared with corresponding data in Fig. 8 and Fig. 9 as these experiments were done simultaneously. For representative images of the control cohort, please refer to Fig. 8 and Fig. 9. Scale bar, 75 μ m. n=4-6 mice/group. Data represents mean±sem. 1 way Anova; ****p<0.0001; ***p<0.001; **p<0.01; **p<0.01; **p<0.05.

Expanded View Table Legends.

 Table EV1. Normalized RNA levels (FKPM values) of Abi3 and Gngt2 from TgCRND8 mice at various ages

 Table EV2. Normalized RNA levels (FKPM values) of Abi3 and Gngt2 from rTg4510 mice at various ages

Table EV3. Analysis of Abi3 and Gngt2 expression changes in mouse studies (transcriptomic data originally reported by Wan et al. [32] and Al Ouran et al [33] and available at

http://mmad.nrihub.org)

Table EV4. Description of resources and reagents used in this study.

Abbreviations

+/+	wild type for Abi3-Gngt2
+/-	haploinsufficient for Abi3-Gngt2

-/-	complete deficiency of Abi3-Gngt2
AAV	adeno-associated virus
Αβ	amyloid β
ABI3	Abelson Interactor Protein 3
AD	Alzheimer's disease
Adamts6	ADAM Metallopeptidase With Thrombospondin Type 1 Motif 6
Adgrf3	Adhesion G Protein-Coupled Receptor F3
Aklr1c13	Aldo-keto reductase family 1 member C13
AMP-AD	Accelerating Medicines Partnership
ARM	Activated response microglia
CER	cerebellum
Chil1	Chitinase-like 1
Clec7a	C-type lectin domain family 7 member A
Cxcr4	C-X-C Motif Chemokine Receptor 4)
DAM	damage associated microglia
DEG	differentially expressed genes
DLPFC	dorsolateral prefrontal cortex
FC	fold change
Fndc9	Fibronectin Type III Domain Containing 9
FPKM	fragments per kilobase of exon per million mapped fragments
GO	Gene Ontology
GFAP	glial fibrillary acidic protein
Gngt2	Guanine Nucleotide Binding Protein Gamma Transducing Activity Polypeptide 2
GS	gene significance value to specific experimental trait
Iba-1	ionized calcium-binding adapter molecule 1
Irf8	Interferon Regulatory Factor 8
Ly86	Lymphocyte Antigen 86
kWithin	extent of gene connectivity within the module

MAF	minor allele frequency
MM	module membership value
MGnD	microglial neurodegenerative phenotype
Mpeg1	Macrophage Expressed 1
MAPT	microtubule associated protein tau
Nramp1	Natural resistance-associated macrophage protein 1
NESH	new molecule including SH3
NFT	neurofibrillary tangles
NonTG	non-transgenic for APPswe/ind (CRND8 line)
ns	non-significant
OR	Odds ratio
Padj	p values adjusted for multiple comparisons
Pcdha5	Protocadherin Gamma Subfamily A 5
PIG	plaque induced genes
QC	quality control
RNA sequencing	RNAseq
S100a9	S100 Calcium Binding Protein A9
SDS	sodium dodecyl sulfate
SH3	Src homology 3
Sval1	seminal vesicle antigen-like 1
TCX	temporal cortex
ThioS	thioflavin S
TG	Transgenic for swe/ind (CRND8)
WGCNA	weighted gene co-expression network analysis
WT	wild type



ר0.5

€ 0.4-

<u>Б</u> 0.3-

Pig 9.2-

0.1- ピ

0.0-Ш

0





**

G


NonT

G

VonT

Б Г

12 mo



b rTg4510 0.3₇

**

**

G

6 mo

*

G

NonT

Б П

3 mo








Figure 1




$\overline{}$ р а \geq \mathfrak{C}









Abi3-Gngt2^{+/+}
 Abi3-Gngt2^{+/-}
 Abi3-Gngt2^{-/-}




σ 0 U) 6


u










< () Ο $\overline{\mathbf{0}}$ \geq










\mathfrak{C}

$\boldsymbol{\omega}$ 0










Figure 3








Figure 4














bioRxiv preprint doi: https://doi.org/10.1101/2021.11.08.467701; this version posted (which was not certified by peer review) is the author/funder, who has granted bioRx

















Figure 5

















*

-/-

APP-Abi3 (+/+)
 APP-Abi3 (+/-)
 APP-Abi3 (-/-)







G


%


Э.


0.

+/+ +/-

-/-







bioRxiv preprint doi: https://doi.org/10.1101/2021.11.08.467701; this version posted November 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 0 deelee Hippocamb

Figure 6








Figure 7





Control/Abi3-Gngt2^{+/+}
 Control/Abi3-Gngt2^{-/-}
 P301L/S320F tau/Abi3-Gngt2^{+/+}
 P301L/S320F tau/Abi3-Gngt2^{-/-}























3000 T


2000-


1000-

 \geq

**

 (\mathbf{O})






*** *** **100** т ***


S


the second the second second




6

bioRxiv preprint doi: https://doi.org/10.1101/2021.11.08.467701; this version poster (which was not certified by peer review) is the author/funder, who has granted bioR available under aCC-BY-NC-ND 4.0 Inte












Figure 8





ဟ






80-









Control/Abi3-Gngt2^{+/+}
 Control/Abi3-Gngt2^{-/-}
 P301L/S320F tau/Abi3-Gngt2^{+/+}
 P301L/S320F tau/Abi3-Gngt2^{-/-}

Iba-1 8 NO

ľ bar

O M S M O M O










Figure 9





ABI3

*

Figure 10




Figure 11